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Pancreatic cancer is the third-leading cause of cancer-related death in the
US and represents a difficult challenge to modern medicine, with increasing
incidence and modest improvements in treatment outcomes. Pancreatic
cancer is characterized by aggressive metastatic progression and high rates
of resistance to chemotherapy, and there are currently no reliable biomarkers
for early detection. In addition, clinicians are faced with difficult decisions
regarding the potential benefit of surgical intervention in high-risk individuals,
as pancreatic resection often has serious side effects. As such, there is an acute
need for the development of improved biomarkers for early detection and to
guide treatment. There is also a need for the development of in vitro models to
study processes that lead to increased complexity in pancreatic cancer, including
processes that lead to increased intra-tumor heterogeneity. The research projects
described in this thesis are centered around the question of how phenotypic
heterogeneity in pancreatic cancer cells influences the performance of platforms
engineered to analyze rare cells in patient blood samples, and the self-assembly
of cancer cells into tumor spheroids.
These endeavors were spurred on by our early observation that circulating
epithelial cells can be isolated from patients with precancerous pancreatic cyst
lesions (Chapter 2), and that analysis of these cell populations may serve
as a biomarker to stratify patients for surgical intervention. In later studies
we have strived to optimize capture of pancreatic circulating tumor cells
in a microfluidic immunocapture platform (Chapter 3), and elucidate what
effect the epithelial to mesenchymal transition (EMT) and the acquisition of
chemoresistance has on its performance (Chapter 4). In parallel, we have
developed in vitro models of resistance to gemcitabine chemotherapy to study
how the associated phenotypic changes lead to changed cell-sorting behavior in
tumor spheroids, and how this influences the response to chemotherapy of the
cancer cell population as a whole (Chapter 5).
In addition to the scientific contributions described in the thesis chapters,
this work has resulted in the development of a range of engineering tools, in
vitro models of EMT and microtumor formation, and the establishment of a
large panel of chemoresistant pancreatic cancer cell lines, all of which can be
used to enable further research into this area.
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CHAPTER 1
INTRODUCTION
1.1 Pancreatic cancer
Pancreatic cancer is the third-leading cause of cancer-related death in US
and is predicted to become the second-leading cause by 2030[1]. In 2016
an estimated 53,000 new cases were recorded, and nearly 42,000 deaths
were attributed to pancreatic cancer, in the US alone[2]. The predicted
increase in overall pancreatic cancer mortality in the coming decades is due to
increased incidence in combination with only minor improvements in treatment
outcomes. Currently the overall 5-year survival rate for pancreatic cancer is
approximately 8%[2].
When diagnosed with pancreatic cancer, patents are stratified in Stages I
to IV; localized and resectable tumor (Stage I and II, 10% of cases), locally
advanced/unresectable tumor (Stage III, 30% of cases) or disseminated disease
with one or more metastatic sites (Stage IV, 60% of cases)[3]. 95% of pancreatic
cancers originate in the exocrine pancreas and 80% of cases are categorized as
pancreatic ductal adenocarcinomas (PDAC)[4], which will be the focus of this
thesis. PDAC is characterized by rapid and aggressive progression[5], and a
majority of patients develop widely metastatic disease with many secondary
lesions[6]. As with other cancer types, metastasis is responsible for a large
majority of pancreatic cancer-related deaths.
PDAC pathogenesis occurs through the development of histologically
distinct precursory lesions, most frequently through the development of
1
Figure 1.1: Progression of pancreatic cancer through precursory lesions
pancreatic intraepithelial neoplasias (PanINs), see figure 1.1. However, a
minority of PDAC tumors develop through intraductal papillary mucinous
neoplasms (IPMNs), and mucinous cystic neoplasms (MCNs)[4]. Unlike
PanINs, IPMNs and MCNs are in many cases detectable through standard
imaging modalities such as CT scans or MRI. PDAC arising from IPMNs and
MCNs tend to be less aggressive than PanIN-derived PDAC, and only a subset
of IPMNs will progress to invasive carcinomas. IPMNs can be resected, but
a significant fraction of resected specimens show no evidence of high-grade
neoplasia and resection comes with significant risk and severe side effects
(brittle diabetes and exocrine deficiency). Patients with IPMNs thus represent
a high-risk population with complicated clinical management and difficult
treatment considerations[7].
As 90% of PDAC patients present with unresectable disease, chemotherapy
is often the only treatment option. Chemotherapy is typically administered
in the form of the nucleoside analog gemcitabine (2’,2’-difluorodeoxycytidine,
dFdC, Gemzar), although other treatment regimens, such as 5FU or
FOLFORINOX, are sometimes used[4]. Recently, a combination therapy of
gemcitabine and nab-paclitaxel (abraxane) has shown increased efficiency[8].
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However, the response to any pancreatic cancer chemotherapy is typically
short-lived and the overall effect on patient survival is modest.
Considering the aggressive nature of metastatic pancreatic cancer and the
poor response to chemotherapy, targeting the process of metastasis itself, the
metastatic cascade, holds a lot of promise for improving the treatment outcomes
of pancreatic cancer.
1.2 The metastatic cascade
The metastatic cascade involves a series of events and processes that result in
the spread of a localized cancer tumor to one or more distant, or metastatic,
sites. Depending on the type of cancer and the tissue of origin, several routes
of metastatic dissemination are possible[9], including dissemination through
the lymphatic system, through shedding of cancer cells into tumor-adjacent
cavities and dissemination through the blood stream. Here, the discussion
will be limited to metastatic spread through the blood stream, referred to as
hematogenous dissemination, a schematic of which can be seen in figure 1.2.
In order for a cancer tumor to metastasize through the blood stream,
cancer cells have to gain the ability to (1) break down the local environment
surrounding the primary tumor, (2) invade into the blood stream, (3) survive
the unfamiliar environment of the circulatory system, (4) avoid detection by
the immune system, (5) successfully lodge at a distant site, (6) break through
the vessel lining into the surrounding tissue (extravasate) and (7) be able to
establish a proliferating secondary lesion at a distant site[10].
3
Figure 1.2: The role of CTCs in the metastatic cascade
Consequently, metastasis is a very inefficient process and only a tiny fraction
of disseminated cancer cells (<0.01%) are thought to have the ability to form a
metastatic lesion[11][10]. The initial steps of the metastatic cascade requires a
breakdown of the epithelial characteristics of the tissue of origin, most notably
the organization of epithelial cells into tightly regulated epithelial sheets.
Several cellular processes are implicated in the development of traits that allow
cancer cells to break down this epithelial structure, including the epithelial to
mesenchymal transition (EMT)[12].
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1.3 The epithelial to mesenchymal transition (EMT) and
chemoresistance
The epithelial to mesenchymal transition (EMT) is a process, first observed in
the context of embryonic morphogenesis, where epithelial cells lose some or all
their epithelial characteristics and develop traits associated with mesenchymal
cells[13][14][15]. More specifically, epithelial cells undergoing EMT lose cell
polarity, cell-cell junctions, association with a basement membrane, and gain
motility, invasiveness, and resistance to anoikis and apoptosis[15]. As such,
EMT leads to the breakdown of the highly organized epithelial tissue. EMT
is implicated in several pathological processes, including fibrosis[16] and
cancer[15]. In cancer, EMT is associated with the onset of metastasis and the
development of chemoresistance[11][17].
Numerous studies have shown that EMT can be induced in some
non-cancerous epithelial cells and cancer cells in vitro by treatment with growth
factors, most commonly TGFβ[18][19][20][21][22][23][24]. As EMT allows for
cancer cells to free themselves of the cell-cell adhesions that normally keep the
integrity of epithelial tissues, EMT is thought to be major contributor to the
dissemination of circulating tumor cells (CTCs) into the blood stream, referred
to as intravasation[11]. In addition, the development of chemoresistance in
vito, particularly to gemcitabine, has been associated with the development of
cellular EMT-characteristics[25][26][27].
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1.4 Circulating tumor cells (CTCs)
Circulating tumor cells (CTCs) are cancer cells that have left the local
environment of a primary tumor or metastatic site, and invaded into the
blood stream. CTCs are believed to be responsible for seeding metastasis
at distant sites[12]. EMT is thought to be necessary for CTC dissemination,
and CTCs displaying mixed epithelial/mesenchymal characteristics have been
widely observed in patient samples[28][29][30] and mouse models of cancer
metastasis[11].
Dissemination of cells from precancerous lesions has been observed in some
contexts[11][31], and these cells are typically referred to as circulating epithelial
cells (CECs) or circulating pancreatic cells (CPCs) (in the context of pancreatic
cysts) rather than CTCs, as they may or may not display carcinogenic traits
and their connection with cancer has not been fully determined. However,
CEC have also been found in non-cancerous inflammatory conditions[32]. In
addition to their proposed mechanistic role in cancer progression, CTCs have
been extensively explored as cancer biomarkers for early detection, prognostics
and prediction of response to therapy, in a wide range of cancer types, including
pancreatic cancer[12].
1.5 CTC isolation methods
The wide range of techniques and platforms have been developed for the
isolation of CTCs from patient blood samples[33]. What underpins the technical
difficulty in isolating CTCs is their extreme rarity. It is estimated that there may
6
be as few as 1 CTC in ten billion blood cells in the peripheral blood of a cancer
patient[12]. The only FDA approved method for CTC isolation is the CellSearch
system. CellSearch uses anti-EpCAM antibody-coated magnetic beads to isolate
CTCs from patient blood samples. CTCs are then identified as CD45-negative
mono-nucleated cells expressing cytokeratin.
Of particular relevance to this thesis are the microfluidic methods for
CTC capture that have been developed over the last decade. Nagrath et
al. demonstrated the first microfluidic chip technology for isolation of CTCs
from whole blood using an array of microposts coated with antibodies[34].
Since then, countless microfluidic platforms for CTC capture have been
developed, most notably the herringbone chip[35], the Vortex chip[36] and
the CTC-iChip[37]. The Kirby Research Group has developed a microfluidic
platform that uses a combination of size-selection and antibody-antigen
recognition to isolate CTC from whole blood, called the Geometrically
Enhanced Differential Immunocapture (GEDI) platform[38][39].
1.6 CTCs in the management of pancreatic cancer
The development of CTC biomarkers for clinical use has attracted intense
interest in the last decade. This is the direct result of a confluence of
developments in the areas of cancer research, clinical care and technical
capabilities. Firstly, as the survival-rates of localized and resectable carcinomas
has increased across the board, metastasis has emerged as the single process
responsible for a vast majority of cancer-related deaths. Biomarkers that are
directly linked to the development of metastasis, such as CTCs, have thus come
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to the forefront of the collective cancer research consciousness.
Furthermore, personalized medicine has been suggested to be the future
of cancer therapy, as patient stratification and targeted therapies have become
increasingly important in the clinical management of many cancer types. As
such, personalized medicine requires more detailed profiling of each patient
than what most standard clinical patient evaluation methods offer. Molecular
profiling of patients requires the access to, and analysis of patient samples,
most often acquired through biopsies. However, it has become evident that
the molecular profile of a patient’s cancer is neither static in time nor space,
as tumor phenotype has been found to vary within a tumor and through
the course of treatment. Fully personalized medicine would thus, require
repeated invasive biopsies to be taken from the patient’s primary tumor and/or
metastatic sites, which is often neither possible nor acceptable to the patient.
CTC isolation and analysis has been suggested as an alternative to traditional
biopsies[32]. Requiring only the collection of a peripheral blood sample, CTC
analysis may serve as a minimally invasive ”liquid biopsy”. This would allow
for CTC biomarkers to be readily incorporated into the clinical care of many
cancer patients, as regular blood draws are already part of standard clinical
cancer management.
In the case of pancreatic cancer, the limited response to treatment in
many patients, and the often very aggressive course of the disease, often
prevents attempting multiple therapies in a step-by-step fashion to find an
effective treatment[40]. Tumor tissue would be valuable for monitoring patient
response to therapy, however the pancreas is inaccessible for biopsy without
surgical intervention. In this context, a minimally invasive biomarker that can
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help guide clinical decision-making could be transformative. In pancreatic
cancer, the correlation between size of the primary tumor and the disease
aggressiveness and clinical outcome, is weaker than in many other cancer
types[31][11]. It is often observed that patients present with multi-focal
metastatic disease with only a small primary pancreatic tumor. Standard
imaging modalities that measure static tumor size or tumor load may thus be
intrinsically less relevant to pancreatic cancer than biomarkers that incorporate
functional information. CTCs represent one such class of real-time biomarkers
that are directly linked to the disease mechanism that ultimately leads to patient
death.
CTCs are of key disease mechanistic importance, as a subset of CTCs are
believed to give rise to distant metastasis[11]. Metastasis is responsible for
more than 90% of deaths associated with pancreatic cancer, and a large majority
of patients present with metastatic disease. In addition, CTC dissemination
has been shown to occur early in pancreatic carcinogenesis in both mouse
models and human cancer patients[11]. These factors make CTC biomarkers
especially advantageous in the early detection of pancreatic cancer. CTC
biomarkers can thus be approached from both the perspective of targeting the
small subpopulation of CTCs believed to seed distant metastases, as well as the
overall CTC load and phenotype. While the former is relevant to early disease
and early detection, the latter may directly measure how active a patient’s
cancer is and thus be relevant to late stage disease and response to treatment.
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1.6.1 Pancreatic CTC biomarkers for screening and diagnostics
CTC capture and identification from patient blood samples could potentially
be used to screen patients for carcinogenesis. However, due to the relatively
low, albeit rising, incidence of pancreatic cancer, and the cost associated
with CTC analysis, a general CTC-based screening approach for pancreatic
cancer is currently not feasible. CTC biomarkers may, however, be useful for
screening patients with increased risk, complementary to standard imaging
modalities such as MRI and endoscopic ultrasound. Unfortunately, relatively
few risk factors for pancreatic cancer are known. However, risk factors
for pancreatic cancer include a strong history of pancreatic cancer (familial
pancreatic cancer) and a few rare hereditary conditions, including Peutz-Jeghers
syndrome, hereditary pancreatitis, hereditary p16 mutations, BRCA1 and
BRCA2 mutations[41]. As circulating epithelial cells have been found in patients
with precancerous pancreatic conditions[31], circulating cell biomarkers may
be useful in the monitoring and risk stratification of patients known to be at
increased risk. To date, no studies have been published examining the presence
of circulating cells in patients with known risk factors for hereditary or familial
pancreatic cancer. This is most likely a direct result of these conditions being
very rare, and sporadic pancreatic cancer (pancreatic cancer with no known risk
factors) accounting for 95% of cases[42].
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1.6.2 CTCs as prognostic and predictive biomarkers in
pancreatic cancer
CTCs have been found to be prognostic in many human cancers,
including breast[43], prostate[44], non-small-cell lung cancer[45] and colorectal
cancer[46]. However, CTCs have been proven to be relatively difficult to isolate
from pancreatic cancer patients as compared to other cancers, such as breast
and prostate cancer. This observation has not been fully explained but the
hypovascularization observed in many pancreatic tumors, direct shuttling of
pancreatic CTCs to the liver through the portal vein and early onset of EMT,
making CTCs undetectable by conventional CTC capture platforms, have been
suggested as potential partial explanations.
A number of studies have aimed to determine the prognostic potential
of CTCs and disseminated cells in PDAC, with varying and sometimes
contradictory results[47][48][49][50][51][52][53][54][55][56][57]. A large portion
of this variation can be explained by considering the diverse set of technologies
utilized to isolate and analyze CTCs, the variation in the definition of what
is considered to be a CTC and the difference in the composition of the
patient group studied. Most studies use antibody-antigen recognition or
size-based technologies to enrich their samples for CTCs. Downstream of
enrichment, CTCs are in many cases identified using immunostaining criteria,
or through detection of some CTC surrogate marker, such epithelial-specific
mRNA transcripts. The wide range of technologies and CTC identification
criteria used make interpreting results of CTC studies challenging, and studies
should thus to be compared in the context of that particular technology and
11
CTC criteria. There is currently no consensus if CTCs are useful prognostic
biomarkers in the clinical management of pancreatic cancer. Several studies
have aimed to determine if CTC analysis can be used a predictive markers
of response to chemotherapy in pancreatic cancer[58][53][40], showing, among
other things, that the number and phenotype of CTCs present in blood changed
after patients were started on chemotherapy.
1.6.3 Pancreatic CTCs as predictive biomarkers of benefit of
resection in precancerous patients
The vast majority (90%) of patients diagnosed with pancreatic ductal
adenocarcinoma present with locally advanced or metastatic disease[3]. For
the minority of patients that present with localized disease, resection is usually
recommended[59]. The decision of whether to resect or not is thus in most cases
made only based on if the disease is localized or not, and if the patient is fit
enough to benefit from the procedure. There is thus currently no need for a
CTC biomarker to guide this decision.
However, there are patient groups where whether or not to resect a
pancreatic abnormality is a more ambiguous question. Pancreatic cyst lesions
represent a group of cystic abnormalities that are relatively common in the
general population, of which a subpopulation will progress into cancer. The
two main subtypes are intraductal papillary mucinous neoplasms (IPMNs) and
mucinous cystic lesions (MCNs)[7]. IPMN lesions are pre-cancerous lesions
that display some cancer like traits such as increased proliferation (neoplasia),
and will in some patients develop into invasive ductal carcinoma with poor
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patient survival and limited response to treatment. Pancreatic cysts are typically
detected in patients during routine imaging procedures, such as CT or MRI
scans. To evaluate the risk of progression and thus also the potential benefit of
resecting the cyst, a rigorous set of criteria are used[7]. These criteria, known
as the Sendai criteria, evaluate the cyst using standard imaging modalities
to determine the size and localization of the cyst and weigh in the presence
or absence of symptoms. Despite their rigor, the Sendai criteria only predict
carcinogenesis in 60% of resected specimens. This means that for a significant
portion of patients that undergo resection, no direct benefit can be shown.
Bearing in mind that pancreatic resection is an invasive procedure with several
common complications, including brittle diabetes and exocrine insufficiency,
there is a strong incentive for the development of biomarkers that can predict
the presence of carcinogenesis in pancreatic cysts and predict benefit of
resection. As mouse model work has shown that CTC dissemination can occur
prior to tumor formation[11], CTC biomarkers represent an attractive avenue to
explore for the development non-invasive biomarkers in pre-cancerous at-risk
patients. A pilot study of circulating epithelial cells in patients with pancreatic
cyst lesions is described in Chapter 2.
1.7 Summary of introduction
Pancreatic cancer represents a difficult challenge to modern medicine, driven
in large part by the early onset of metastatic disease and high rates of
chemoresistance. Gemcitabine chemotherapy is the standard of care but
suffers from limited efficacy. Metastasis is responsible for a vast majority of
cancer-related deaths. However, the process of metastasis is very inefficient
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and requires the interaction of multiple complex processes at different length
scales. Circulating Tumor Cells (CTCs) are key players in the metastatic
cascade and constitute a rare population of disseminated cancer cells present in
peripheral circulating of cancer patients. A small fraction of CTCs are thought
to give rise to metastasis by establishing secondary tumors at distant sites. The
dissemination of CTCs is thought to require the loss of epithelial characteristics
and a gain in mesenchymal traits. This phenotypic switch is thought to in part
be orchestrated by a processes called the epithelial-to-mesenchymal transition
(EMT). In addition to facilitating CTC dissemination, EMT has been linked to
the development of chemoresistance. A wide range of techniques, including the
GEDI microfluidic device, have been developed to isolate CTCs from patient
samples. CTCs have been explored as biomarkers for pancreatic cancer in
a variety of clinical settings. In particular CTCs show promise in the early
detection setting and as a potential biomarker of early pancreatic carcinogenesis
in high-risk patients. However, the effect of EMT and chemoresistance on
the performance of CTC isolation techniques has not been fully investigated.
Furthermore, EMT and chemoresistance are known to dramatically alter the
phenotype of cancer cells and can thus be expected to influence cancer cell
behavior on many levels.
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CHAPTER 2
DETECTION OF CIRCULATING PANCREAS EPITHELIAL CELLS IN
PATIENTS WITH PANCREATIC CYSTIC LESIONS
This chapter adapted from the article
Andrew D. Rhim, Fredrik I. Thege, Steven M. Santana, Timothy B. Lannin,
Trisha N. Saha, Shannon Tsai, Lara R. Maggs, Michael L. Kochman, Gregory
G. Ginsberg, John G. Lieb, Vinay Chandrasekhara, Jeffrey A. Drebin, Nuzhat
Ahmad, YuXiao Yang, Brian J. Kirby, and Ben Z. Stanger, Detection of
Circulating Pancreas Epithelial Cells in Patients With Pancreatic Cystic
Lesions. Gastroenterology 119 (2014). doi:10.1053/j.gastro.2013.12.007
2.1 Abstract
Hematogenous dissemination is thought to be a late event in cancer progression.
We recently showed in a genetic model of pancreatic ductal adenocarcinoma
that pancreas cells can be detected in the bloodstream before tumor formation.
To confirm these findings in humans, we used microfluidic geometrically
enhanced differential immunocapture to detect circulating pancreas epithelial
cells in patient blood samples. We captured more than 3 circulating pancreas
epithelial cells/mL in 7 of 21 (33%) patients with cystic lesions and no clinical
diagnosis of cancer (Sendai criteria negative), 8 of 11 (73%) with pancreatic
ductal adenocarcinoma, and in 0 of 19 patients without cysts or cancer
(controls). These findings indicate that cancer cells are present in the circulation
of patients before tumors are detected, which might be used in risk assessment.
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2.2 Contributions to this chapter
Andrew Rhim and Brian Kirby were responsible for the study concept, analysis,
and interpretation of data; Andrew Rhim, Michael Kochman, and Brian Kirby
were responsible for the study design; Andrew Rhim, Michael Kochman,
Gregory Ginsberg, John Lieb, Vinay Chandrasekhara, Jeffrey Drebin, Nuzhat
Ahmad, Trisha Saha, Shannon Tsai, and Lara Maggs were responsible for
patient enrollment; Andrew Rhim, Fredrik Thege, Steven Santana, Timothy
Lannin, Michael Kochman, Brian Kirby, Trisha Saha, and Shannon Tsai were
responsible for the acquisition of data; Andrew Rhim and YuXiao Yang were
responsible for the statistical analysis; Andrew Rhim was responsible for the
drafting of the manuscript; Andrew Rhim, Fredrik Thege, Michael Kochman,
Gregory Ginsberg, Vinay Chandrasekhara, Jeffrey Drebin, YuXiao Yang, Brian
Kirby, and Ben Stanger were responsible for critical revision of the manuscript.
2.3 Results and Discussion
A widely accepted paradigm in cancer biology is that epithelial cancers
progress in a linear manner whereby cancer-defining properties are acquired
sequentially[60]. In this model, cancer cells acquire metastatic potential
after large primary tumors are established. However, in pancreatic ductal
adenocarcinoma (PDAC), the linear progression model cannot be reconciled
with clinical observations. A number of patients undergoing pancreatectomy
for chronic pancreatitis will develop disseminated PDAC, although only
precancerous pancreatic intraepithelial neoplasias, but no tumors, are found
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on histologic analysis[61]. In addition, in patients with small primary tumors
(<2 cm) who have no clinical evidence of metastatic disease, 5-year survival
after pancreatectomy is less than 18% owing to recurrent metastatic disease[62].
These data suggest that metastatic seeding may occur before the formation
of large primary tumors. Moreover, we recently showed that hematogenous
dissemination occurs before tumor formation, in a lineage-labeled genetic
model of PDAC[11], at which time the pancreas contained only pancreatic
intraepithelial neoplasias. Based on the clinical characteristics of PDAC and
our findings within a recapitulative mouse model, we hypothesized that
bloodstream seeding of pancreas-derived epithelial cells can occur in patients
with clinical evidence of only precancerous lesions of the pancreas and no
detectable invasive carcinoma. To test our hypothesis, we performed a
blinded prospective pilot study of 3 cohorts, as follows: (1) patients with
no history of cancer presenting for average-risk, age-appropriate colonoscopy
screening and no adenomas detected; (2) patients with precancerous cystic
lesions (intraductal papillary mucinous neoplasm [IPMN] or mucinous cystic
neoplasms) of the pancreas with no evidence of tumor or metastasis on
computerized tomography or magnetic resonance imaging, who did not
qualify for surgery using the Sendai criteria[63] (including no evidence of
dysplasia or cancer on fine-needle aspiration, if performed); and (3) patients
with cytology-confirmed PDAC. Peripheral blood was obtained from patients
who consented before the procedure. We analyzed blood samples using
geometrically enhanced differential immunocapture (GEDI), a microfluidic
platform that has been shown to detect circulating tumor cells from patients
with prostate cancers with high sensitivity[38][39]. Here, we functionalized the
GEDI device using antibodies to epithelial cell adhesion molecule to capture
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circulating epithelial cells (CECs). Captured cells then were stained with
4’,6-diamidino-2-phenylindole (DAPI) to visualize nuclei and fluorescently
conjugated antibodies to CD45, a universal marker of leukocytes, and
cytokeratin 19 (CK), a marker of epithelial-derived cells or pancreatic and
duodenal homeobox protein-1 (Pdx-1), a pancreas-specific transcription factor.
A blinded observer (B.J.K.) enumerated CECs using the following 2 definitions:
(1) CD45-, DAPI+, and (2) CK+,CD45-,DAPI+ using a fluorescence microscope.
Definition 1 was confirmed retrospectively with automated cell enumeration
and 4-color immunofluorescence for epithelial and pancreas-specific markers.
Figure 2.1: Table of enrolled patients
We prospectively enrolled 48 patients (Table 1). Cyst- and cancer-free
patients tended to be younger compared with the cystic lesion and PDAC
cohorts (P 0¯.003). However, there were no differences in other demographics.
18
Figure 2.2: Table of enrolled patients, cont’d
Most (85%) cystic lesions were classified as side-branch IPMNs. The size of
cystic lesions varied from 5 to 28 mm. Patients with PDAC had a wide range
of primary tumor diameters (15-91 mm) and tumor stages (I-IV). Sixteen of 19
cancer-free controls had no CECs by either definition, see figure 2.3B. When
CECs were detected, there were no more than 3/mL. Seven of 9 (78%) patients
with PDAC had detectable CECs, with an average of 16.2 ± 19.5 CEC/mL
blood (P < 0.0001 compared with cancer-free patients by the MannWhitney test).
Eight of 21 (40%) patients with cystic lesions of the pancreas had detectable
CECs, averaging 4.5 ± 7.3 CECs/mL blood (P = 0.022 compared with cancer-free
patients), and there was a significant difference in CECs across the 3 groups by
1-way analysis of variance (P = 0.015). Interestingly, there was no significant
difference in the number of CECs detected among cyst lesion patients based on
the immunofluorescence definition used (figure 2.3B; black denotes definition
1, red denotes CEC analysis from different patients using definition 2); that is,
a similar percentage of cyst lesion patients contained CECs by either definition,
and, when CECs were detected in these patients, a similar concentration was
found. We found no correlation with CEC count and tumor or cyst size, cancer
stage or serum carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic
antigen.
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Figure 2.3: Detection of CECs in patients using GEDI. a) Depiction of the
GEDI device. b) Vertical scatterplots of CEC concentrations (per milliliter
blood) for cancer-free patients (control), patients with cystic lesions of the
pancreas without dysplasia or tumor (cystic lesion), and patients with PDAC.
Bars indicate statistically significant differences using the MannWhitney test.
Representative images of individual GEDI-captured nucleated cells from c) PI34
cells in culture, d) control human blood spiked with PI34 cells and e) blood
from a patient with PDAC. Cells were stained for CD45 (green), Pdx-1 (red),
and DNA (DAPI, blue). Scale bar: 20 mm.
To confirm the pancreas origin of CECs, we stained cells for Pdx-1, a
pancreas-specific transcription factor, expressed in up to 60% of all CECs in
mouse models of PDAC4 (figure 2.3B). Adherent and GEDI-captured primary
PDAC cells also expressed nuclear Pdx-1 (21% of PI34 and 10.7% of Panc-01;
figure 2.3C). However, no nuclear Pdx-1 was detected within human breast
(MCF-7) or prostate (LNCaP, CWR22Rv1) cancer cells or CD45+ leukocytes
(data not shown). These data suggest that Pdx-1 is a specific marker of
pancreas-derived cells. In our analyses, 29% of all CECs showed nuclear
Pdx-1 staining (figure 2.3D). These data confirm that at least a portion of
all GEDI-captured epithelial cells derive from the pancreas. In conclusion,
we report that pancreas epithelial cells can enter the bloodstream in patients
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with cystic lesions of the pancreas before the clinical diagnosis of cancer.
By using state-of-the-art microfluidic technology and immunofluorescence
staining, we confirmed the pancreas origin of captured CECs. Thus, these
findings suggest that the ability to seed the bloodstream may precede the
formation of detectable tumors, supporting our findings in genetic mouse
models of PDAC[11]. These data are supported by the recent finding that 24.6%
of resected side-branch IPMNs that do not satisfy Sendai criteria contain regions
of high-grade dysplasia or invasive carcinoma[64]. Data from our mouse model
predict that these cells represent early, occult cancer cells[11], although we do
not yet have evidence to support this in human beings. Studies are underway
to interrogate the genomic signature of CECs from cystic lesion patients. If
these cells represent the earliest forms of cancer, we predict that they would
contain a complement of somatic mutations associated with PDAC. Genomic
analyses of CECs represent a technical challenge that recently was addressed
elegantly using massively parallel sequencing of RNA from captured tumor
cells from patients with PDAC[65]; however, cyst lesion patients contain many
fewer CECs, complicating genomic analysis. Furthermore, it is still unknown if
patients with CECs are destined to form tumors. If associated with sub-sequent
tumor formation, CEC detection could be used as a biomarker for cancer risk
stratification in patients at risk for PDAC. Studies underway in this regard will
prospectively follow GEDI-analyzed cystic lesion patients to determine if CEC
number or genomic analysis are predictive of an eventual diagnosis of PDAC.
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CHAPTER 3
MICROFLUIDIC IMMUNOCAPTURE OF CIRCULATING PANCREATIC
CELLS USING PARALLEL EPCAM AND MUC1 CAPTURE:
CHARACTERIZATION, OPTIMIZATION AND DOWNSTREAM
ANALYSIS
This chapter adapted from the article
Fredrik I. Thege, Timothy B. Lannin, Trisha N. Saha, Shannon Tsai, Michael
L. Kochman, Michael A. Hollingsworth, Andrew D. Rhim, and Brian J. Kirby,
Microfluidic immunocapture of circulating pancreatic cells using parallel
EpCAM and MUC1 capture: characterization, optimization and downstream
analysis, Lab on a Chip (2014). doi:10.1039/c4lc00041b
3.1 Abstract
We have developed and optimized a microfluidic device platform for the
capture and analysis of circulating pancreatic cells (CPCs) and pancreatic
circulating tumor cells (CTCs). Our platform uses parallel anti-EpCAM and
cancer-specific mucin 1 (MUC1) immunocapture in a silicon microdevice. Using
a combination of anti-EpCAM and anti-MUC1 capture in a single device we
are able to achieve efficient capture while extending immunocapture beyond
single marker recognition. We also detect a known oncogenic KRAS mutation
in cells spiked in whole blood using immunocapture, RNA extraction, RT-PCR
and Sanger sequencing. To allow for downstream single-cell genetic analysis,
intact nuclei were released from captured cells by use of targeted membrane
lysis. We have developed a staining protocol for clinical samples, including
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standard CTC markers; DAPI, cytokeratin (CK) and CD45, and a novel
marker of carcinogenesis in CPCs, mucin 4 (MUC4). We also demonstrate a
semi-automated approach to image analysis and CPC identification, suitable for
clinical hypothesis generation. Initial results from immunocapture of a clinical
pancreatic cancer patient sample show that parallel capture may capture more
of the heterogeneity of the CPC population. With this platform we aim to
develop a diagnostic biomarker for early pancreatic carcinogenesis and patient
risk stratification.
3.2 Contributions to this chapter
Fredrik Thege, Andrew Rhim and Brian Kirby were responsible for study
idea. Fredrik Thege was responsible for study design. Andrew Rhim,
Michael Kochman, Trisha Saha and Shannon Tsai were responsible for patient
enrollment. Fredrik Thege was responsible for the acquisition of data and
statistical analysis. Timothy Lannin was responsible for developing automated
imaging and image analysis software and code.
3.3 Background and introduction
Pancreatic cancer (PC), the fourth leading cause of cancer-related death in the
US and is associated with a poor 5-year patient survival rate of less than 5%.
PC is characterized by rapid and often symptom-free progression, resulting
in more than 90% of patients being diagnosed with metastatic disease[66], a
stage at which there are no effective treatment options. Clinical data show
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that the treatment outcome improves dramatically if PC is caught at an early
stage, prior to the formation of clinically-detectable metastasis[66][67]. Early
detection is thus the most efficient way to improve overall patient survival,
but detection is limited by the absence of specific clinical biomarkers and
non-invasive screening tests[67].
The formation of metastasis is attributed to the intravasation of cells from
the primary site of disease into the blood stream, followed by transport to
a secondary site where the cells extravasate, proliferate and form secondary
lesions[68][69][70]. These cells are in general referred to as circulating tumor
cells (CTCs). Here, we refer to any cell that disseminates from the pancreas into
the blood stream as a circulating pancreatic cell (CPC). Recent results in a mouse
model that recapitulates human pancreatic carcinogenesis have shown that
dissemination of cells from the pancreas occurs prior to tumor formation[11].
Furthermore, we have recently shown that epithelial pancreatic cells can be
found in the circulation of patients with pancreatic cyst lesions in the absence
of overt tumor formation, making CPCs a more appropriate term for this cell
population[31]. In future studies, early dissemination of CPCs could thus offer
partial explanation to the rapid and aggressive progression observed in PC
patients. Precancerous CPC dissemination also allows for the development of
early detection biomarkers of pancreatic carcinogenesis.
CTCs have been shown to be prognostic of patient survival in a number
of cancers and are suggested to be of disease mechanistic importance and of
diagnostic value[71]. The extreme rarity of CTCs in peripheral circulation
makes CTC isolation technically challenging. To allow for their efficient
isolation, a range of microfluidic platforms have been developed[33]. These
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platforms have explored a range of physical principles and geometries to
achieve efficient and pure isolation, including; micropillar arrays[34][38][72],
vortex-inducing microgrooves[35], microsieves and filters[73][74], magnetic
microbeads[75] and inertial separation[36]. Some techniques rely solely on
passive separation of CTCs based on physical parameters such as cell size
and stiffness. However, a majority of techniques use an optimized surface
capture chemistry to achieve CTC isolation. Immunocapture using surface
functionalization of capture antibodies has emerged as the dominant technique
for isolating CTCs in microfluidic devices[33] and relies on the collision of
target cells with a immunofunctionlized surface. In these devices, the geometry
serves to maximize the interaction of target cells with the capture chemistry.
We have previously described one such geometry[38][39], that maximizes the
cell-capture surface interaction of larger cells, such as CTCs, in combination
with an optimized CTC capture chemistry. The choice of capture chemistry
influences the resulting population of captured cells and needs to be optimized
for each application and disease studied. Antibodies for different cancer and
epithelial markers, such as epithelial cell adhesion molecule (EpCAM)[31][34],
prostate specific membrane antigen (PSMA)[38][39], Her2[76][29] and EGFR[29]
have been used to capture CTCs from a range of cancers. Due to their inherent
difference in specificity and binding affinity the choice of antibody clone has
been shown to dominate capture performance[77]. In the case of prostate
cancer, the use of the tissue specific marker PSMA has been shown to result
in superior capture as compared to capture using the commonly used marker
EpCAM[39]. The capture chemistry should thus ideally be optimized for each
specific application and for a specific cancer type. Here we aim to show that
using recognition of a combination of two markers, both upregulated in PC,
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we can achieve efficient CPC capture. We also aim to show that the choice of
capture chemistry governs the phenotype of captured cells.
As previously stated, EpCAM is the most widely used target for
immunocapture of CTCs[34][35][78][38]. However, there is mounting evidence
that EpCAM is downregulated in CTCs from some clinical samples[29] and
during the cancer-associated process referred to as epithelial-to-mesenchymal
transition (EMT)[68], making EpCAM capture alone a potential source of bias
for the capture of CPCs. In cancerous and precancerous tissues, EMT results
in the development of an invasive phenotype[11][79][80] and has been shown
to correlate with cancer progression[29]. On a cellular level, EMT results in
the loss of epithelial markers and an upregulation of mesenchymal markers,
as well as a gross change in cell morphology[11][79]. Furthermore, because
recent PC mouse model data indicate the a vast majority of CPCs display an
EMT phenotype, anti-EpCAM capture alone may fail to capture this potentially
clinically significant CPC subpopulation. Breast cancer patient CTCs have been
shown to express a dynamic range of EMT composition in a way that correlates
with treatment outcome[29]. There is thus a pressing need to find alternative
and/or complementary, EMT-robust capture modes. In this study we explore
parallel anti-EpCAM and anti-mucin capture as a promising novel capture
chemistry.
Mucins are a family of high-molecular-weight glycoproteins that are
expressed by epithelial tissues, such as the respiratory and gastric linings
as well as the ducts of the liver and pancreas, where they protect and
lubricate the surfaces[81]. The founding member of this protein family, mucin
1 (MUC1) is expressed at a low level in healthy pancreas tissue, but has
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been shown to be strongly upregulated in pancreatic carcinogenesis[81][82].
Furthermore, overexpression of MUC1 has been shown to increase cancer
cell invasiveness and motility through the induction of EMT in a PC mouse
model[83]. MUC1 expression in CTCs from metastatic pancreatic patients
has also been associated with shorter median overall patient survival[50].The
cancer-associated post-translational modification of MUC1 differs significantly
from MUC1 found in healthy tissues[84]. Cancer-associated MUC1 is typically
aberrantly hypoglycosylated[85][86] and the loss of cell polarity that occurs
during carcinogenesis results in expression of MUC1 uniformly covering the
cell membrane rather than being restricted to the apical side of the epithelial
cell[86]. Furthermore, the aberrant expression pattern and hypoglycosylation
of MUC1 exposes regions of the protein backbone to antibody binding,
allowing for the creation of cancer-specific antibodies that bind minimally to
MUC1 from healthy tissues[85][86]. An antibody specific to hypoglycosyled
MUC1 (hMUC1) has previously been shown to induce cell adhesion when
functionalized to the surface in a E-selectin cell-rolling assay[87]. Although
MUC1 has been observed on the surface of some activated T-cells[88], the MUC1
expression level is low and of a distinct glycoform[89], making hMUC1 cancer
cell specific in blood samples. Together, the strong upregulation, cancer-specific
hypoglycosylation and change in spatial distribution, make hMUC1 an ideal
target for the capture of CPCs in early carcinogenesis, allowing for the
exploration of the link between capture chemistry and resulting phenotype of
early disseminated CPCs.
The clinical implementation of a CPC capture platform relies on the specific
and robust identification of captured CPCs and rejection of contaminating
leukocytes. Cytokeratin (CK) is an epithelial marker that is frequently used as a
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positive marker of CTCs[34]. However, CK has in patient samples been shown
to be downregulated more than EpCAM during EMT[90]. Mucin 4 (MUC4)
has been shown to be differentially upregulated in pancreatic carcinogenesis;
MUC4 is not expressed by healthy pancreatic tissues but strongly upregulated
in cancerous and precancerous neoplastic pancreatic lesions[84][91][92]. Since
CK expression may be lost during pancreatic carcinogenesis, we suggest
using CK and MUC4 as orthogonal positive indicators of CPC identity. The
relationship between CK and MUC4 expression level in the CPC population
may also be an indicator of the EMT state of the CPCs and thus be of
prognostic importance. Since MUC4 expression has been shown to increase
progressively in precancerous pancreatic neoplasias[91], the presence or
absence of CPC MUC4 expression may be used for risk stratification of patients
with precancerous conditions.
Despite the fact that enumeration of CTCs has been shown to be a prognostic
biomarker in a number of common cancers, CTC enumeration has not yet
been incorporated into standard clinical practice in the management of any
cancer[32]. However, the integration of genetic analysis in parallel with
cell enumeration may allow for the development of stronger biomarkers and
incorporation of these in clinical practice[93]. The genetic analysis of CPCs
may reveal early signs of pancreatic carcinogenesis, before any cancer is
clinically observable, without requiring an invasive biopsy. Moving beyond
CTC enumeration, genetic analysis can provide information about prognosis
and disease progression. Genetic mutations in circulating cell populations
have shown to be prognostic of treatment outcome in lung cancer[93]. The
technical difficulty associated with genotyping circulating cells is considerable,
owing to their rarity and the presence of contaminating wild-type genetic
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material. Point mutations in circulating cell have been analyzed using
mutation-specific qPCR[93]. A drawback of this approach is that it relies
on the recognition of known SNPs using mutation-specific primers. As an
alternative to genetic analysis, a mutational protein-level approach has recently
been described, using an antibody specific to a mutated protein in the lysate
from circulating cells[74]. However, this methodology relies on the availability
of mutation-specific antibodies, only available for a subset of SNPs. Direct
genetic sequencing represents the gold standard for genotyping and requires
no previous knowledge of the particular mutation of interest. However, direct
sequencing is sensitive to the presence of wild-type genetic material in the
sample and can only be used in samples of high purity, i.e. if the number of
mutated molecules is comparable to number of the wild-type molecules. In this
respect, RNA level analysis may be more feasible than genomic level analysis
as the mRNA copynumber of upregulated oncogenes, such as KRAS, can be
assumed to be significantly higher in cancer cells compared to the wild-type
cells.
Activating KRAS mutations represent some of the most common mutations
in human carcinomas[94]. The KRAS gene encodes a small GTPase signaling
protein that plays a fundamental role in cell growth regulation. KRAS
mutations are found in more than 85% of patients with PC and in approximately
80% of patients with high-risk precancerous cystic lesions[94]. The molecular
profiles of activating KRAS mutations are well described and a vast majority
of mutations occur in codon 12 and 13 of the KRAS gene[95], which makes
them suitable for analysis with RT-PCR-based amplification followed by genetic
sequencing.
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We have developed a microfluidic platform optimized to capture, identify
and genotype CPCs, building on our previously described Geometrically
Enhanced Differential Immunocapture (GEDI) device[39][38][72]. In this
platform we explore capture chemistry as a design parameter and study its
influence on the phenotype of captured cells. Our platform uses a combination
of anti-EpCAM and anti-hMUC1 capture and allows for the release of intact cell
nuclei and downstream KRAS oncogene genotyping.
3.4 Materials and methods
Device fabrication and functionalization
Devices were fabricated by A.M. Fitzgerald & Associates (Burlingame, CA)
according to previously described specifications[38][39]. The silicon device
surfaces were functionalized with NeutrAvidin (Thermo Fisher Scientific,
Rockford, IL) with a previously described protocol[39]. The devices were
functionalized with primary antibodies via biotinylated secondary linker
antibodies. NeutrAvidin functionalized devices were (1) incubated with
10 µg/ml biotinylated goat anti-mouse antibody (Santa Cruz Biotechnology,
Dallas, TX) and (2) incubated with either 10 µg/ml anti-EpCAM antibody
(Clone 158206, R&D Systems, Minneapolis, MN), 10 µg/ml anti-MUC1
antibody (AR20.5) or 5 µg/ml anti-EpCAM and 5 µg/ml anti-MUC1 antibody.
Control devices were functionalized with biotinylated normal (non-specific)
mouse antibodies (Santa Cruz Biotechnology). All antibodies were prepared
in 1% BSA in PBS.
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Cell culture
Cell lines (Capan-1, PANC-1 and BxPC-3) were obtained from ATCC (Manassas,
VA). All cell lines were cultured in humidified incubators (37 ◦C and 5% CO2)
using media recommended by ATCC (Capan-1: 20% FBS IMDM, PANC-1: 10%
FBS DMEM and BxPC-3: 10% FBS RPMI) and 1X penicillin/streptomycin. Cells
were used only below passage number 30 and cells were harvested after 4-6
days of culture at 60-80% confluency.
Quantitative flow cytometry
Cells were trypsinized for 5-10 minutes at 37 ◦C and then fixed with the
Foxp3 fixation/permeabilization kit (eBioscience, San Diego, CA). Staining was
performed with 0.5µg primary antibody/106 cells and 0.2µg PE-conjugated
secondary antibody/106 cells in blocking flow cytometry staining buffer
(eBioscience). Analysis was performed on a LSRII flow cytometer (BD
Biosciences, San Jose, CA) and PE-Quantibrite beads (BD Biosciences) were
used to quantify the antibodies bound per cell (ABC) count for this staining
protocol. Data processing and calculation of the ABC counts were performed
with custom MATLAB software.
Capture experiments
Cells were trypsinized for 5-10 minutes at 37 ◦C, labeled with 2µg/ml Calcein
AM (Santa Cruz Biotechnology) for 45 minutes and resuspended in carrier
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solution (1% BSA, 1 mM EDTA in PBS) at approximately 300 cells/ml.
Peripheral blood mononuclear cells (PBMCs) were isolated from donor blood
using Ficoll centrifugation, labeled with CellTracker orange (Invitrogen, Grand
Island, NY) and resuspended at approximately 500 cells/ml. Functionalized
silicon devices were mounted with Tygon tubing inlets and outlets in a PMMA
holder. Cell capture was achieved by flowing 1 ml cell suspension through
the device at 1 ml/h followed by manual cell enumeration using fluorescence
microscopy.
Isolation of captured nuclei
Targeted cell membrane lysis and release of nuclei from captured cells was
performed using overnight incubation with a modified NST buffer (117mM
NaCl, 8 mM Tris base, 0.8mM CaCl2, 38 mM MgCl2, 0.04% BSA, 0.16% NP-40
surfactant in DI water) with and without DAPI (10µg/ml), based previously
described method[96].
RNA sequencing
RT-PCR primers were designed to amplify a 249 bp fragment containing
codon 12 of human KRAS using the NCBI primer-BLAST tool; forward:
GGAGAGAGGCCTGCTGAAAA and reverse: CCCTCCCCAGTCCTCATGTA.
The forward primer was designed to overlap on neighboring KRAS exons to
increase the RNA specificity of the RT-PCR amplification. Calcein labeled
Capan-1 cells were spiked in control blood at 300 cells per ml. The cells
were captured using anti-EpCAM GEDI. After washing with PBS and cell
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enumeration, RNA was extracted directly on-chip using the RNEasy kit
(Qiagen). Extracted RNA from whole blood and Capan-1 cells spiked
in PBS served as wild type and positive controls respectively. RT-PCR
of extracted RNA was performed using a single tube reaction and the
recommended protocol (OneStep, Qiagen); reverse transcription 30 min at
50 ◦C, PCR activation 15 min at 95 ◦C, 35 cycles of denaturation 45 s at 94 ◦C,
annealing at 45 s at 61 ◦C and extension 1 min at 72 ◦C, followed by final
extension 10 min at 72 ◦C. Successful KRAS cDNA amplification was confirmed
using agarose gel separation. RT-PCR products were treated with alkaline
phosphatase and exonuclease (ExoSAP-IT, Affymetrix) to remove remaining
primers from RT-PCR reaction. Sequencing of GEDI captured samples and
whole blood controls was performed by the Cornell Life Sciences Core Facility
on an automated 3730xl DNA analyzer (Invitrogen), using Big Dye terminator
chemistry, the reverse primer used for RT-PCR as sequencing primer and
AmpliTaq-FS DNA polymerase (Invitrogen)
Capture and staining of clinical samples
Blood was obtained through venipuncture of a patient with clinically
confirmed pancreatic ductal adenocarcinoma (PDAC). 1ml blood was processed
through GEDI devices functionalized with anti-EpCAM, anti-hMUC1 and
anti-hMUC1/EpCAM antibodies. Samples were fixed in 2% PFA in 50%
PHEM buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA and 2 mM
MgCl2) for 15 minutes and blocked in 6% BSA and 10% normal goat serum
in PBS for 1 hour. After staining of surface markers, the samples were
permeabilized with 0.25% (w/w) Triton x-100. The samples were stained
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for MUC4 with a primary (ab60720; abcam, Cambridge, MA, USA) and an
AlexaFluor 488 conjugated secondary antibody (Invitrogen), for CD45 with a
Qdot-800 conjugated antibody (Invitrogen), for CK using a CF543 (Biotium,
Hayward, CA, USA) conjugated anti-pan-CK antibody (C11; BioLegend, San
Diego, CA, USA) and for DNA/nuclei using DAPI (Invitrogen). Samples were
collected, processed, fixed and stained within 48h.
Clinical sample analysis
Stained samples were imaged using a Zeiss LSM Live Confocal Microscope
(10x 0.3NA). All cell-sized DAPI+ events with brightness DAPI and CK barely
above the background noise were identified using image processing in a
custom MATLAB algorithm. The prescreened events were then classified
as CPCs or non-CPCs using manual classification. DAPI+/CD45-/CK+,
DAPI+/CD45-/MUC4+ and DAPI+/CD45-/CK+/MUC4+ were used as CPC
criteria.
3.5 Results and discussion
Expression analysis in model cell lines
A panel of three PC cell lines (Capan-1, PANC-1 and BxPC-3) where used as
models for CPCs in the development of the capture methodology. These cell
lines represent cells isolated from both primary pancreatic tumors (PANC-1
and BxPC-3) and liver metastasis (Capan-1); cells in different states of
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differentiation: Capan-1 (well differentiated), BxPC-3 (moderately to poorly
differentiated) and PANC-1 (poorly differentiated); and varying mutation status
of key oncogenes (KRAS, TP53, CDKN2A/P16 and SMAD4)[97] as well as
distinct levels of MUC1 expression[98].
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Figure 3.1: Calibration of the antibody bound per cell (ABC) count for
determination of antibody binding in PC cell lines, a) histogram showing gated
flow cytometry data of phycoerythrin (PE) labeled Quantibrite beads of four
intensity levels (black), Capan-1 cells stained with control (red) and hMUC1
(blue) antibodies a) calibration of the ABC count with PE-Quantibrite beads.
The expression level of EpCAM and hMUC1 was determined with
quantitative flow cytometry for all three cell lines, as shown in figure 3.1.
Quantitative flow cytometry determines the antibodies bound per cell (ABC)
count of a population of cells calibrated using beads with known numbers of
bound fluorescent molecules. Candidate antibodies for immunocapture were
selected based on strong and consistent staining across all three cell lines.
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One anti-EpCAM (Clone 158206 mouse mAb, R&D) and one anti-hMUC1
(AR20.5[85] mouse mAb) antibody were identified as promising candidate
antibodies for immunocapture. Figure 3.2 shows the resulting ABC counts
for these antibodies and cell lines. Since we ultimately aim to determine
the influence of capture chemistry design on resulting phenotype of captured
cells, the choice of model cell lines is important. In addition to the reasons
mentioned above, the flow cytometry results show that this panel of cell
lines displays a wide range of expression levels of EpCAM and hMUC1.
In our experiments, Capan-1 cells displayed the strongest staining for both
EpCAM and hMUC1 whereas PANC-1 stained the weakest for both, with
ABC counts ranging from ∼10,000 to ∼70,000 for the three cell lines. Previous
studies have reported EpCAM ABC counts in the range of 2,000 to 500,000
in a variety of cancer cell lines[74]. Interestingly, the relative hMUC1 ABC
counts between cell lines do not correlate with previously described mRNA
expression levels of these cell lines[98]. We attribute this difference to intrinsic
differences in mRNA and surface antigen quantification, the specific fixation
protocol used as well as differences in MUC1 glycosylation, accumulation and
turn-over. Previous work has highlighted the utility of EpCAM capture[99]
for immunocapture of CTCs from many carcinomas, but the role of MUC1
remains less clear. Cocktail capture has been presented in multiple contexts[29].
However, parallel anti-EpCAM/hMUC1 capture has not been implemented in
microdevice technology to date and this strategy allows implementation of a
novel capture modality in a new device.
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Figure 3.2: Antibody bound per cell (ABC) counts for EpCAM, hMUC1 and PE
labeled secondary control antibodies in cell lines Capan-1, PANC-1 and BxPC-3
Microfluidic immunocapture of model cell lines
We have previously described the GEDI capture geometry in detail[39]. In
short, the GEDI device[38][39][100] is a microfluidic chip that captures rare
cells from blood or cell suspensions, as shown in figure 3.3a. GEDI uses
the combination of cancer-specific antibody immunocapture with a micropost
geometry that maximizes the collision frequency between the substrate and
larger cells (e.g., CTCs), and minimizes collisions of smaller contaminating
cells (e.g. leukocytes). We have previously described the GEDI platform in
a prostate[39][77], breast [76] and gastric[76] cancer context. We have shown
how biotinylated antibodies can be functionalized onto NeutrAvidin coated
silicon surfaces[39][77]. However, biotinyation of low concentration antibody
samples requires high antibody purity and is typically inefficient. Biotinylated
versions of primary antibodies are often not commercially available. As an
alternative, we have here developed a protocol that attaches primary antibodies
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to silicon surfaces via biotinylated secondary antibody linkers, omitting any
modification of the primary antibody. Figure 3.3c shows a schematic of the
functionalization chemistry used. Using this approach, we have implemented
anti-EpCAM/hMUC1 modalities because of their importance in PC. We expect
new anti-EpCAM/hMUC1 devices will enable investigation of questions
regarding heterogeneity in CTCs in PC.
b)
Primary antibody 
(mouse anti-human)
Secondary antibody 
(goat anti-mouse)
Biotin linker
Immobilized NeutrAvidin®
Silicon surface
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Figure 3.3: a) schematic overview of the GEDI device, modified from Kirby et
al.[39], microposts not to scale b) calcein-stained (green) PANC-1 cell captured
on a GEDI micro post functionalized with a cancer-specific MUC1 antibody.
Scale bar: 20 µm c) silicon surface functionalization with primary antibodies and
secondary antibody linker chemistry that allows for multiple parallel capture
antibodies.
To determine the efficiency of immunocapture in this system, fluorescently
labeled cells were resuspended in buffer solution at physiologically relevant
levels (300 cells/ml) and processed through GEDI devices, followed by manual
counting. A representative image of a PANC-1 cell captured on GEDI micropost
can be seen in figure 3.3b. We hypothesize that anti-hMUC1 capture alone or in
combination with anti-EpCAM capture will capture a more clinically relevant
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population of CPCs as compared to anti-EpCAM capture alone. To evaluate
capture performance, we have determined the capture efficiency for all three
scenarios, while ensuring that the total amount of antibody in the incubation
solution was constant between experiments. As expected, anti-EpCAM alone
resulted in efficient immunocapture while anti-hMUC1 capture alone resulted
in lower capture efficiencies. However, a 1:1 antibody cocktail of anti-EpCAM
and anti-hMUC1 performed indistinguishably from anti-EpCAM capture alone.
Figure 3.4a shows the resulting capture efficiencies from EpCAM, hMUC1
and EpCAM/hMUC1 cocktail capture. These results show that for these
three cell lines, cocktail EpCAM/hMUC1 capture could replace the current
EpCAM gold standard for immunocapture, without reducing capture efficiency.
Furthermore, in a clinical scenario where EpCAM expression is reduced as a
result of EMT while MUC1 expression is retained or upregulated, as is expected
from clinical data[82], the capture performance of the EpCAM/hMUC1 cocktail
may result in improved capture performance. Cocktail capture has been
explored both for multiple epitopes on a single antigen[77] and for multiple
antigens[29]. For single antigens, the data to date shows no synergy[77]. For
multiple antigens, the data to date shows potential to capture more of the
heterogeneity expected in the CTC population[29]. However to our knowledge,
no published study has thoroughly examined the effect of using multiple
capture antibodies on the resulting capture efficiency as a function of cellular
antigen expression level and cell size.
Our capture data show that Capan-1 and PANC-1 display EpCAM capture
efficiencies more than twice that of BxPC-3, despite that fact that PANC-1
cells have lower EpCAM and hMUC1 ABC counts than the corresponding
counts for Capan-1 and BxPC-3. This behavior can be explained by considering
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Figure 3.4: a) GEDI microdevice immunocapture of Capan-1, PANC-1
and BxPC-3 cells by anti-EpCAM and anti-hMUC1 antibodies, and an
anti-EpCAM/hMUC1 antibody cocktail, b) anti-EpCAM capture efficiencies
of Capan-1, PANC-1 and BxPC-3 cells and predicted collision frequency as
function of cell size, based on previously described simulations [72]. ∗ indicates
statistically significant difference with p=0.05
the size distribution of the cell populations and the predicted size-dependent
performance of our device[72]. The predicted collision frequency and the
experimentally observed capture efficiencies as function of cell size can be
seen in figure 3.4b. Previously described simulations predict a sharp transition
from low to high collision frequency for cells larger than 15µm[72]. We have
measured the diameter of trypsinized populations of BxPC-3, Capan-1 and
PANC-1 cells to be 13.3±2.9 µm,15.8±3.2 µm and 17.3±2.7 µm respectively. The
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majority of BxPC-3 cells will thus fall below the cutoff cell size of our device
geometry, resulting in low collision rates and capture efficiencies lower than
for the two cell lines with mean diameters larger than 15 µm. In the design
regime of this platform, size dominates over relative levels of capture target
expression provided that the cells express some minimum level of the capture
target. Unlike staining for flow cytometry, for which antibodies are freely
suspended in solution and can reach sterically obstructed epitopes through
diffusion, antibodies for immunocapture are immobilized on surfaces allowing
only for binding of epitopes that are pendant on the outer surface of the cell
membrane. It is thus expected that some strongly staining antibodies will fail
to result in efficient immunocapture. The resulting capture efficiency depends
on the abundance and accessibility of antibody binding sites on the target cells.
Since the saturation density of antibodies functionalized on the device surface is
finite, the use of multiple capture antibodies reduces the surface density of each
antibody type. In order for the addition of an additional parallel capture mode
to increase capture efficiency, the gain in number and accessibility of possible
capture targets has to outweigh the loss of capture efficiency that results of
having fewer antibody molecules of each type on the surface. An example
of a case where the addition of a second antibody leads to reduced capture
efficiency can be seen in a previous capture study, conducted in a Hele-Shaw
flow microdevice[77]. In that case, the second antibody was specific to a
juxtamembranous epitope on the same target molecule as the first antibody. The
total number of available target molecules thus remained unchanged with the
addition of the second antibody, but the overall accessibility of binding sites was
reduced, resulting in lower overall capture efficiency. In our case, the addition
of a hMUC1 antibody to EpCAM capture increases the total number of available
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binding sites on each cell, as both EpCAM and hMUC1 are expressed strongly.
The net result is that the overall capture efficiency for cocktail capture is retained
as compared to anti-EpCAM and increased as compared to anti-hMUC1 capture
alone. Given the natural variation in capture marker expression level between
cells, the targeting of multiple highly-expressed capture targets will work to
increase the robustness of capture to this intercellular variation. We thus
conclude that a combined EpCAM and hMUC1 strategy has the potential to
increase the robustness of capture to CPC heterogeneity and EMT, without
reducing the overall capture efficiency as compared to the gold standard
anti-EpCAM capture.
The most common source of cell contamination in microfluidic immunocapture
devices is, due to their abundance as compared to rare circulating cells, the
nonspecific adhesion of leukocytes[39]. Anti-EpCAM capture is widely used
for immunocapture and results in only nonspecific adhesion of leukocytes.
To ensure that the same is true for anti-hMUC capture, we conduced
capture experiments using isolated donor peripheral blood mononucleated cells
(PBMCs) in mixed populations with Capan-1 cells. The results showed that
PMBCs adhered to our device at equal and negligible rates for both antibodies.
Isolation of captured cell nuclei
Recent studies have shown that breast cancer CTCs display genetic
heterogeneity similar to that of primary and metastatic breast cancer
tumors[101]. To analyze the heterogeneity within the CPC population single
cell genetic analysis is required. To facilitate the future development of such
a methodology we have developed a protocol for the release and isolation of
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single nuclei from captured cells on chip. Using targeted cell membrane lysis,
followed by elution and retrieval of the nuclei through centrifugation, we have
shown successful isolation of intact nuclei from captured cells. Examples of
released and isolated nuclei can be seen in figure 3.5a.
Genetic analysis
Genetic analysis of captured CPCs is technically challenging due to the low
number of cells present in blood and the presence of background wild-type
genetic material from contaminating leukocytes. However, we have previously
showed SNP detection of a mutated gene with amplified copynumber in
captured cells, spiked in control blood[39]. To show ability to detect mutations
in the important oncogene KRAS in small numbers of captured cells in the
presence of a whole blood background, we used a PC cell line with known
KRAS codon 12 mutation signature (Capan-1, GGT→GTT substitution) spiked
in control blood. Calcein labeled cells were spiked in whole blood from a
healthy donor (300 Capan-1 cells/ml control blood). RNA from captured cells
was extracted directly on chip followed by RT-PCR and Sanger sequencing,
the resulting KRAS codon 12 RT-PCR amplicons and Sanger sequences from
250 anti-EpCAM captured Capan-1 cells spiked in blood and buffer as well as
whole blood wild type control are shown in figure 3.5b and c. RNA from whole
blood showed no evidence of KRAS mutations while RNA extracted on chip
from Capan-1 cells captured in buffer and whole blood revealed the expected
GGT→GTT SNP in codon 12 of KRAS. In summary, these experiments show
our ability to retrieve, amplify and analyze the genetic information from a very
small number (<300) of captured cells even in the presence of contaminating
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wild-type genetic material.
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Figure 3.5: a) released and isolated DAPI-stained (blue) Capan-1 nuclei, b)
agarose gel with a 249 bp Capan-1 KRAS RT-PCR product from cells spiked
in PBS buffer and whole blood, c) Sanger sequencing of the KRAS codon 12
RT-PCR product from whole blood, Capan-1 cells spiked in PBS and Capan-1
cells spiked in whole blood. The whole blood sequence shows the wild type
codon 12 genotype (GGT) while RNA extracted from Capan-1 cells spiked in
PBS and whole blood show the expected GGT→GTT oncogenic SNP. Note the
presence of a small wild-type peak in the spiked blood sample. The presented
sense sequences have been converted from anti-sense sequences generated by
the Sanger sequencing reaction
Analysis of clinical samples
To show technical capability of capturing CPCs from clinical samples, we
analyzed the blood from a patient with clinically confirmed pancreatic
ductal adenocarcinoma (PDAC) using anti-EpCAM, anti-hMUC1 and cocktail
anti-EpCAM-hMUC1 capture. After processing through the GEDI devices,
the samples were fixed and stained. DAPI staining was used to indicate cell
nucleus and CD45 antigen staining was used to identify and reject leukocytes,
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as previously described[39]. All samples were stained for both CK and MUC4.
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Figure 3.6: Analysis of CPCs from a clinical PDAC patient sample, processed
using anti-EpCAM, anti-EpCAM/hMUC1 and anti-hMUC1 GEDI devices, a)
ratio of total MUC4 and CK staining intensity versus nuclear DAPI area in
events classified as likely CPCs, b) inset images showing representative CPC
events, i-ii anti-EpCAM/hMUC1 cocktail capture, iii-iv anti-hMUC1 capture
and v-vi anti-EpCAM capture, images i,iii and iv are consistent with cells spread
on microposts, DAPI (blue), cytokeratin (red), MUC4 (green). Scale bar: 10 µm
c) mean MUC4-to-CK total intensity ratios for all three capture modes, error
bars indicate standard deviation within the population of identified CPCs
Nuclear-like DAPI+ events were identified with an automated algorithm.
Remaining events were classified manually with CD45-/CK+ and/or
CD45-/MUC4+ as CPC criteria, resulting in between 102 and 165 events
identified as likely CPCs per milliliter blood in this sample. Figure 3.6 shows
that, in this patient sample, events identified as likely CPCs from devices
functionalized with anti-hMUC1 and anti-EpCAM/hMUC1 cocktail capture
show increased MUC4 to CK intensity ratios relative to anti-EpCAM capture
alone. This indicates that, in this sample, anti-hMUC1 capture results in capture
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of a cell population that is positive for both CK and MUC4. It is possible
that this DAPI+/CD45-/MUC4+/CK+ cell population is of important clinical
significance as MUC4 expression correlates with PC progression. Data from
this sample shows that the apparent heterogeneity of the captured CPCs, as
measured by the range of MUC4 staining in the captured CPCs, is larger
in the anti-hMUC1 and EpCAM/hMUC1 samples than in the anti-EpCAM
sample. Using this semi-automated approach to image analysis, we generate
data suitable for clinical hypothesis generation. The resulting data can be gated
and visualized like flow cytometry data and the phenotype of individual cells,
as well as cell populations and subpopulations can be analyzed. The automated
pre-screening of CPC events also greatly reduces the time and labor required
for manual classification.
3.6 Conclusions
We have demonstrated a novel microfluidic platform for the capture and
analysis of circulating pancreatic cells. This platform builds on a previously
described geometry but incorporates novel anti-hypoglycosylated mucin 1
capture chemistry and explores parallelized EpCAM/hMUC1 capture as a
novel capture paradigm. We show that a combination of anti-EpCAM and
anti-hypoglycosylated mucin 1 capture performs as well as anti-EpCAM
capture alone in model cell lines, while potentially increasing the robustness
to variations in marker expression and EMT. To allow for the development of
single-cell genetic analysis of circulating cells, we show release and isolation
of single nuclei from captured cells. Using on-chip RNA extraction, RT-PCR
and Sanger sequencing, we detected a known oncogenic KRAS SNP mutation
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in captured cells spiked in whole blood. We have also developed a staining
protocol for clinical samples that involves standard circulating tumor cell
makers, such as DAPI, CD45 and cytokeratin as well the PC-specific marker
mucin 4. In an initial clinical sample, cocktail capture resulted in the capture
of a cell population distinct from anti-EpCAM capture. Our approach allows
for analysis of single cells and cell populations from patient samples and is
suitable for clinical hypothesis generation. In all, we have shown feasibility
of this platform for future evaluation in a clinical setting.
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CHAPTER 4
ELUCIDATING THE EFFECT OF EMT AND CHEMORESISTANCE ON
PANCREATIC CTC IMMUNOCAPTURE
4.1 Abstract
Capture and analysis of circulating tumor cells bears promise for improving
patient monitoring and guiding treatment in patients with pancreatic cancer.
A majority of CTC analysis techniques rely on the recognition of epithelial
markers, particularly EpCAM and cytokeratin for CTC identification. As the
epithelial-to-mesenchymal transition and acquisition of chemoresistance both
have been shown to lead to loss of epithelial markers, the effect of these
processes on CTC capture and identification needs exploration. Here, we have
developed in vitro models of EMT and gemcitabine resistance, and using these
models we show that EMT-induction and chemoresistance cells leads to loss
of EpCAM capture performance while EGFR capture is more robust to these
processes.
4.2 Background and Introduction
Pancreatic cancer is a devastating disease with a 5-year survival rate of about
8%[2] and is predicted to become the second-leading cause of cancer-related
death by 2030[1]. Early onset of metastatic disease and high rates of intrinsic
and acquired resistance to chemotherapy (chemoresistance) represent major
challenges to improving treatment outcomes[102]. A large majority of patients
are diagnosed at the metastatic stage, where the tumor has spread beyond
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the pancreas and cannot be surgically removed[103], leaving chemotherapy
as the only treatment option. Consequently treatment of pancreatic cancer is
hampered by the lack of early detection modalities and biomarkers to guide
treatment.
Capture and isolation of circulating epithelial cells (CECs) has been
proposed as a potential biomarker of early pancreatic carcinogenesis[11]. We
have previously shown that CECs are disseminated into the blood stream in
some patients with precancerous pancreatic cyst lesions and can be isolated
using anti-EpCAM immunocapture in our Geometrically Enhanced Differential
Immunocapture (GEDI) platform[31][104]. Furthermore, we have shown that
anti-EpCAM capture can be used in combination with other capture modalities,
such as anti-MUC1, to capture a wide range of pancreatic cancer cells[104].
However, the question of which CTC markers are ideal for CTC immunocapture
remains to be determined. Anti-EpCAM immunocapture remains the gold
standard for CTCs capture, despite growing evidence that CTC EpCAM
expression is heterogeneous and in many cases absent[105][39].
One process that has been linked to loss of EpCAM expression in carcinoma
cells is the epithelial-to-mesenchymal transition (EMT)[106]. EMT involves
the downregulation of epithelial markers (e.g. E-cadherin and cytokeratin)
and upregulation of mesenchymal markers (e.g. vimentin and N-cadherin), as
well as the acquisition of a fibroblast-like morphology and a gain in migratory
and invasive traits[15]. EMT is controlled by transcription factors, including
Zeb1, Snail, Twist and can be triggered by stimulation of growth-factors (e.g.
TGFβ and EGF) in some cancer cells[18][107][23]. As EMT results in the loss
of epithelial markers, such as CTC markers EpCAM and cytokeratin, it has
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significant implications on the performance of CTC capture techniques that rely
on these markers.
The remarkably early onset of the epithelial-to-mesenchymal transition
(EMT) in pancreatic cancer is thought to contribute to the early metastasis
observed in most patients[11]. EMT is thought to be necessary for intravasation
of carcinoma cells into the blood circulation[11] and to contribute to pancreatic
chemoresistance[17][102]. The role of EMT in pancreatic cancer is still debated
and a recent study suggested that the main contribution of EMT to cancer
progression is due to its connection to chemoresistance rather than by enabling
metastasis[17].
The canonical definition of a CTC as a nucleated, EpCAM-expressing,
cytokeratin positive and CD45 negative cell in circulation makes CTC isolation
susceptible to processes that influence the expression of these markers.
There is a growing body of evidence showing that patient CTCs display
significant heterogeneity and this strict CTC-definition likely leaves many
CTC populations undetected[106]. Although purely epithelial or mesenchymal
CTCs are present in patient samples, CTCs displaying mixed epithelial and
mesenchymal phenotypes are often found[28][29][30]. It has been hypothesized
that since EMT represents a key step in the metastatic cascade, CTCs displaying
some degree of EMT-induction or mixed phenotype may have increased clinical
and pathological significance[108]. In addition, the current understanding of
the importance and prevalence of EMT in CTCs is biased as a majority of
isolation methods used in previous studies rely on recognition of markers
known to be lost during EMT.
Heterogeneity of EpCAM and cytokeratin expression has been observed
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in patient CTCs, across several cancer types[105][39]. We have, for example,
previously identified CTCs lacking EpCAM expression in samples from
prostate cancer patients, captured using anti-PSMA GEDI[39].
In addition, the EMT status of CTCs has been observed to change over time
and in response to treatment. In particular, the mesenchymal CTC subtype has
been shown to correlate with cancer progression[29]. To accurately monitor
a patient’s cancer using CTC analysis, the CTC isolation and identification
platform thus has to capture this variation in CTC phenotype and not be
sensitive to changes in CTC EMT status. One approach to overcome the
issues with single-marker capture is to use a combination of markers for
CTC capture[104], a combination of EpCAM, HER2 and EGFR has been used
successfully in breast cancer[29]. Although, the use of markers other than
EpCAM and using several markers in combination may increase the robustness
to variations in CTC marker expression, the effect on the performance of a CTC
isolation platform of using such markers has yet to be thoroughly evaluated.
Another process know to profoundly change the properties of cancer cells
and the expression of surface markers is the acquisition of chemoresistance. For
a large majority of patients with pancreatic cancer, chemotherapy in the form of
gemcitabine mono- or combination-therapy is the only treatment option, with
only a modest positive effect on patient survival[102]. Gemcitabine (Gemzar,
2’,2’-difluorodeoxycytidine, dFdC) is a nucleoside analog that induces cell death
by terminating DNA replication and inhibiting ribonucleotide reductase (RNR),
a key enzyme required for DNA synthesis[109]. The gemcitabine molecule
is a prodrug that requires intracellular activation to become biologically
active. Intracellular activation occurs through the sequential phosphorylation
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of gemcitabine into the corresponding mono-, di- and triphosphates (dFdCMP,
dFdCDP and dFdCTP), of which the first and rate-limiting phosphorylation
reaction is catalyzed by the enzyme deoxycytidinekinase (dCK)[109]. Previous
studies have shown that loss of dCK expression results in strong gemcitabine
resistance in vitro[110].
Although multiple different resistance mechanisms are indicated in
gemcitabine resistance, acquired resistance to gemcitabine has in some
cases been correlated with the acquisition of an EMT-like phenotype[26][27].
Furthermore, recent work has shown the importance of EMT in the
development of chemoresistance in pancreatic cancer, suggesting an intrinsic
connection between EMT and chemoresistance[17].
In summary these observations emphasize the need for a better
understanding of how the phenotypic heterogeneity of cancer cells, induced
by processes such as EMT and acquisition of chemoresistance, influences CTC
capture and identification platforms. Here, we describe the development of
an in vitro model of EMT-induction and acquired gemcitabine resistance in
pancreatic cancer cells. Using this model we evaluated the performance of
anti-EpCAM and anti-EGFR immunocapture in the GEDI microfluidic CTC
immunocapture platform. Our results show that anti-EGFR is more robust
to EMT and acquired resistance to gemcitabine as compared to anti-EpCAM
capture.
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4.3 Materials and Methods
Cell culture
PANC-1, BxPC-3, MIAPACA-2 and Capan-1 cells were acquired from
ATCC and were cultured following ATCC recommendations; PANC-1 and
MIAPACA-2 in DMEM with 10% FBS, BxPC-3 in RPMI-1640 with 10% FBS,
and Capan-1 in IMDM with 20% FBS. All cells were cultured with 100 units
penicillin, 0.10 mg streptomycin and 0.25 g amphotericin B per ml in a 5% CO2,
37◦C humidified incubator.
EMT induction
For EMT-induction, cells were seeded at 500,000 cells per 60mm dish and
allowed to grow for 48h. Cells were then replated at 6,000 cells/cm2 and treated
with 10ng/ml TGF-beta (R&D Systems) and/or 20ng/ml EGF (R&D Systems)
in media supplemented with 2.5% FBS over a period of 7 days, replacing the
media every other day.
Generation of gemcitabine resistant cell lines
Gemcitabine resistant sub-clones of PANC-1 cells were generated by exposing
naive cells to low doses of gemcitabine over a total of 10 months. Emerging
resistant clones were isolated and subcultured.
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Immunofluorescence
Cells were grown in optical-bottom 96-well plates (Thermo). Following
washing with PBS, cells were fixed with 2% formaldehyde in a PBS/PHEM
buffer (60 mM PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2). Cells
were then blocked with 10% normal donkey serum for 45 minutes at room
temperature, followed by permeabilization with 0.1% saponin for 5 minutes.
Cells were permeabilized only when staining for intracellular markers or with
cocktails of EMT marker antibodies. Following permeabilization, cells were
incubated overnight at 4◦C with anti-N-cadherin (R&D Systems), anti-vimentin
(Santa Cruz, Santa Cruz, CA), anti-E-cadherin (CellSignaling, Beverly, MA),
anti-pan-CK (BioLegend, San Diego, CA), anti-EpCAM (R&D) and anti-EGFR
(C225, Millipore) antibodies. Cells were then incubated with Alexa Fluor 488,
568 or 647-conjugated secondary antibodies (Life Technologies, Grand Island,
NY) for 1 hr at room temperature. Cells were counterstained with 1ug/ml DAPI
(Sigma-Aldrich, St. Louis, MO) for 15 minutes. Representative images were
then acquired using a Nikon Eclipse TE2000-U fluorescent microscope.
Spreading assay
Cells were seeded sparsely in 96-well plates. When small colonies (5-10 cells)
had formed, 10 ng/ml TGF-beta was added to the culture media. The individual
colonies were then followed over 72h and spreading was assed by manual
inspection.
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Western blotting
Cells were seeded in at 500,000 cells/60mm in tissue culture treated dishes
48h prior to harvest of protein lysates. Before lysis, cells were washed with
ice-cold PBS followed by complete removal of the supernatant. 100ul lysis
buffer (50 mM Tris, 1% (v/v) Triton X-100, 150 mM NaCl, 2mM PMSF, 1mM
sodium orthovanadate and 1X protease inhibitor cocktail from Santa Cruz
Biotechnology) was then added per plate. Cells were lysed by mechanical
disruption using a cell scraper. Lysates were pipetted 10 times with a 1000ul
pipettor to homogenize. Lysates were then incubated on ice for 20 min with
constant rocking and intermittent vortexing. Insoluble cellular components
were removed by spinning the raw lysates at 15,000xg, for 9 minutes at 4◦C.
The lysates were then stored at -80◦C or used right away. Following protein
quantification with the DC protein assay (Bio-Rad), lysates were heat treated
in Laemmli sample buffer (2% SDS, 2% 2-mercaptoethanol, 0.1% bromophenol
blue, 10% glycerol, 62.5 mM Tris-HCl) in a dry bath set to 98◦C for 5 minutes.
10-15 ug total protein per well was then loaded in 4-20% Tris-Glycine gradient
polyacrylamide gels (Thermo). The Bio-Rad Kaleidoscope protein ladder was
used as positive control. SDS-PAGE ran at 160V on ice for approximately
1h and 45min in running buffer (25 mM Tris-HCl, 190 mM glycine, 0.1%
SDS). Proteins were then transferred to 0.45um PVDF blotting membranes
(Millipore) by electrophoresis at 400mA for 1h and 45 min in transfer buffer
(25 mM Tris-HCl, 190 mM glycine, 0.1% SDS, 20% methanol) with constant
water cooling. Following protein blotting, the membranes were washed in
TBST buffer (20 mM Tris-HCl, 150 mM NaCl, 0.1% (v/v) Tween 20) and
blocked for 2h in 3% BSA-TBST. Staining with primary antibodies over night
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at 4◦C with constant rocking. Primary antibodies used: anti-RRM1 (EPR8483,
abcam), anti-RRM2 (N1C1, GeneTex), anti-dCK (Bethyl), anti-β-actin (D6A8,
abcam). Following washing, the membranes were stained with HRP-conjugated
secondary antibodies for 1h at room temperature. Blots were developed with
Western Lightning Plus Enhanced Chemiluminescence Substrate (Perkin Elmer)
and autoradiographical film (add company).
Flow cytometry
Cells were seeded in at 500,000 cells/60mm in tissue culture treated dishes, 48h
prior to flow cytometry. Following trypsinization, cells were blocked on ice for
30 minutes in 2% FBS in PBS. For EpCAM and EGFR, cells were then incubated
with 1ug primary antibody/1e6 cells for 1 hour on ice, followed by washing
and incubation with 1ug/1e6 cells PE-conjugated goat anti-mouse secondary
antibody (SCBT) in 2% FBS in PBS for 1 hour on ice. Antibodies bound per cell
(ABC) counts were determined with PE Quantibtite beads (BD) according to
manufacturers description. For cytokeratin staining, cells were fixed for 15 min
in 4% PFA in PBS. Following washing, cells were incubated with 1ug/1e6 cells
CF568-conjugated (Biotium) pan-reactive cytokeratin antibody (C11, Biolegend)
in a buffer containing 2% FBS and 1mg/ml saponin in PBS for 1 hour on ice.
Immunocapture
GEDI microdevices were functionalized with anti-EpCAM (R&D Systems)
or anti-EGFR (C225, Millipore) antibodies using a previously described
protocol[104]. Briefly, silicon devices were manufactured by AM Fitzgerald
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and Associates with Bosch etch on SOI substrates and functionalized with
antibodies using consecutive incubation with 4% (v/v) 3-(mercaptopropyl)
trimethoxysilane (Sigma) in ethanol, 0.28% (w/v) GMBS (Sigma) in ethanol,
25ug/ml Neutravidin (Thermo) in PBS, 10ug/ml biotinylated goat anti-mouse
antibody (SCBT) in 1%BSA in PBS and 10 ug/ml EpCAM or EGFR antbody
in 1%BSA in PBS. For capture performance and cell enumeration experiments
cells were labeled with 4µM Calcein AM for 30min prior to spiking in running
buffer. Approximately 300 cells/ml were spiked in PBS containing 1% BSA and
1mM EDTA, and subsequently captured in GEDI devices, followed by manual
counting of calcein positive cells.
4.4 Results and Discussion
Expression of CTC markers in pancreatic cancer cell lines
Efficient CTC immunocapture relies on the recognition of surface markers
expressed by CTCs but not by other cells present in blood. The epithelial
cell marker EpCAM is the most commonly used capture marker for CTCs,
but other markers such as EGFR[29], MUC1[104] and HER2[76] have also
been used[29]. Following capture using positive selection, CTCs are typically
distinguished from white blood cells using staining for cytokeratin (CK), a
family of epithelial-specific cytoskeletal proteins and CD45, a pan-leukocyte
marker absent on epithelial cells. EpCAM and CK expression have been shown
to vary greatly in patient CTCs[105][39][90][51][30], and certain cancer-related
processes, such as EMT and acquired chemoresistance, have been shown to
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influence the expression of these markers[106][11]. Here, we measured the
baseline expression of EpCAM and CK in three pancreatic cancer cell lines, as
well as in the context of EMT and chemoresistance. In addition, we explored
EGFR as a possible alternative capture marker, or complement to anti-EpCAM
capture.
First, we determined the baseline expression of EpCAM, EGFR and CK in
a panel of pancreatic cancer cell lines that span the range from epithelial-like
to mesenchymal-like morphology and marker expression, see figure 4.1a.
BxPC-3 cells display pronounced epithelial-like traits (epitheloid morphology
and colony formation, high E-cadherin expression, low vimentin and low
N-cadherin expression), whereas MIAPACA-2 cells display a mesenchymal
phenotype (spindle-like morphology, undetectable E-cadherin , high vimentin
and high N-cadherin expression), see figure 4.1a. PANC-1 cells display a mixed
phenotype with epithelial and mesenchymal traits (some epithelial colony
formation, heterogenic E-cadherin expression, high vimentin and N-cadherin
expression).
As can be seen in figure 4.1b, BxPC-3 cells display the highest level
of EpCAM expression whereas MIAPACA-2 cells lack detectable EpCAM
expression, consistent with these cells exhibiting epithelial and mesenchymal
phenotypes, respectively. An intermediate level of EpCAM expression was
found on PANC-1 cells, which is consistent with an intermediate EMT-status.
All three cell lines were found to express significant levels of EGFR, whereas
PANC-1 expressed markedly more than the other cell lines. The level of
EGFR expression did thus not correlate with baseline EMT status in these cell
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Figure 4.1: a) immunofluorescence staining reveal widely varying cellular
phenotypes in the panel of pancreatic cancer cell lines studied: BxPC-3, PANC-1
and MIAPACA-2, b) quantitative flow cytometry shows that all cell lines
expressed significant levels of EGFR, whereas EpCAM expression was detected
in BxPC-3 and PANC-1 but not in MIAPACA-2 cells, c) EpCAM expression
is more variable within the cellular populations tested, as indicated by a
wider histogram of EpCAM expression, as compared to EGFR expression,
d) cytokeratin expression does not correlate with epithelial-like phenotype as
MIAPACA-2 cells express higher levels of cytokeratin than PANC-1 and BxPC-3
lines. Interestingly, we found that in all cell lines the intercellular variability of
EpCAM expression was greater than for EGFR, an example of which can be seen
as a broader EpCAM flow cytometry histogram in figure 4.1c. Considering that
EGFR was present on all the cell lines tested, and that EGFR expression showed
59
less intercellular variability than EpCAM in these cell lines, indicates that EGFR
may be a more universal capture marker for pancreatic CTCs. All cell lines
were found to express cytokeratin, however, the level of cytokeratin expression
did not correlate with baseline EMT-status. PANC-1 cells expressed the highest
level of cytokeratin as measured by flow cytometry, followed by MIAPACA-2
and BxPC-3, see figure 4.1d.
EMT is thought to be a dynamic and in some cases reversible process[15].
Growth factor signaling in the tumor microenvironment could potentially
trigger transient EMT induction[15], leading to intravasation of CTCs into
the blood stream. However, the effect of growth factor-induced EMT on the
expression of CTC markers EpCAM, EGFR and cytokeratin has not to be
determined in these cell lines. It is well established that EMT can be induced
by growth factor stimulation in some cancer cell lines, potentially allowing for
the creation of an in vitro EMT-induction model and the determination of the
effect of EMT on CTC marker expression.
Development of an EMT induction protocol
To determine the effect of EMT on CTC marker expression and immunocapture,
we developed an in vitro EMT-induction protocol using growth factor treatment.
Based on results reported by others[107][23], cells were treated with TGFβ,
alone or in combination with EGF. For these experiments we used a
panel of epithelial-like or mixed-phenotype pancreatic cancer cells: Capan-1
(epithelial-like), BxPC-3 (epithelial-like) and PANC-1 (mixed phenotype).
As can be seen in figure 4.2, we evaluated EMT-induction with staining
for E-cadherin (epithelial marker), vimentin and N-cadherin (mesenchymal
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Figure 4.2: a) EMT-induction was observed in PANC-1 and BxPC-3 cells
following treatment with TGFβ alone or in combination with EGF, b) TGFβ and
EGF stimulation resulted in upregulation of nuclear Zeb1 expression in BxPC-3
cells, c) TGFβ-treatment dramatically alters the morphology of PANC-1 cells,
leading to an acquisition of a mesenchymal morphology, d) colony spreading
was observed in PANC-1 cells following stimulation with TGFβ
markers), using immunofluorescence. Functional EMT was confirmed with a
previously described colony-spreading assay[18].
In concordance with other studies[18], we found that TGFβ alone induced
distinct EMT in PANC-1 cells. In these cells, TGFβ treatment led to a
near complete loss of epithelial-like colony formation and acquisition of a
pronounced mesenchymal-like phenotype, as well as a near-complete loss of
E-cadherin expression and increased expression of vimentin. In this population,
EMT-induction was observed in nearly all cells, as determined by manual
inspection, see figure 4.2a. TGFβ treatment alone did not noticeably alter
the morphology of BxPC-3 or Capan-1 cells, although some upregulation of
vimentin and N-cadherin was observed in BxPC-3 cells, see figure 4.2a. These
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results are consistent with the expected results considering the previously
determined cell line genotypes. PANC-1 cells harbor an activating KRAS
mutation and wt SMAD4, whereas BxPC-3 cells are KRAS wt and SMAD4
deficient, and Capan-1 cells are KRAS activated and SMAD4 mutated[97].
Previous studies have shown that active MAPK/ERK signaling is necessary for
TGFβ induced EMT[21][18], suggesting that BxPC-3 cell may be able to undergo
TGFβ-induced EMT if simultaneously stimulated with EGF. Potent induction
of EMT following treatment of epithelial cells with TGFβ and EGF has been
described previously[107][23], to our knowledge not in the context of pancreatic
cancer. Indeed, we found that BxPC-3 cells could be induced to undergo
EMT when stimulated with TGFβ in combination with EGF, despite reportedly
lacking SMAD4 expression[97]. However, EMT-induction was observed in
only a fraction of cells and some epithelial-like colonies persisted in the cell
population, see figure 4.2.
Although TGFβ signaling is mediated by several pathways down-stream of
ligand/receptor binding, canonical TGFβ signaling occurs through a SMAD4,
mediated pathway[111]. SMAD4 (also known as Deleted in Pancreatic
Carcinoma Locus 4, DPCL4) is often mutated or deleted in pancreatic cancer,
underscoring the importance of the anti proliferative/tumor suppressor role of
TGFβ signaling in early carcinogenesis. However, late in tumor progression
TGFβ is thought to play a role in the metastatic cascade by inducing EMT,
contributing to the dissemination cells from the primary tumor[111]. However,
our finding that BxPC-3 cells can be induced for EMT despite lacking SMAD4
expression is consistent with the increasing appreciation of non-canonical
(SMAD-independent) TGFβ signaling[112][113]. In line with our hypotheses
and the presence of KRAS activating mutations in Capan-1 cells, the addition
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of EGF did not lead to EMT-induction in these cells, potentially due to
disrupted TGFβ signaling. As PANC-1 cells display a mixed EMT phenotype
and responded the strongest to EMT-induction with TGFβ treatment alone,
we decided to use PANC-1 for our future studies of the effect of EMT and
chemoresistance on CTC marker expression and immunocapture.
Development of gemcitabine-resistant subclones
Figure 4.3: a) gemcitabine resistant PANC-1 subclones were generated using
long-term drug exposure and display significantly increased gemcitabine
resistance, as indicated by increased IC50-values, PAGR-560C represents a
heterogeneous mix of resistant and non-resistant cells, PAGR-COL1, COL10
and COL12 represent isolated resistant subclones with IC50-values higher than
1mM, b) PAGR-COL1 cells display significant cross-resistance with cytarabine,
c-d) no significant 5FU or didox cross-resistance was observed in PAGR-COL1
cells, e) PAGR subclones display decreased expression of the gemcitabine
activating enzyme deoxycytidine kinase (dCK), expression level of RRM1 and
RRM2 was unaltered in resistant cells, f) PAGR-COL1 cells display a phenotype
similar to parental PANC-1 cells, scale bar 50µm
Acquisition of gemcitabine resistance has been shown to alter the phenotype
and EMT status of cancer cells in vitro. Several studies have found that
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development of gemcitabine resistance results in the acquisition a migratory
phenotype, with or without increased expression of EMT markers[25][26][27].
With this in mind we aimed to determine what the effect of acquired
gemcitabine resistance is on the expression of CTC markers and CTC
immunocapture of pancreatic cancer cells. First, gemcitabine resistant
subclones of the pancreatic cancer cell line PANC-1 were selected by exposing
cells to increasing levels of gemcitabine, over a course of 10 months.
Several highly resistant subclones (PAGR-COL1-12) were isolated from a
heterogeneouspopulation of resistant cells treated with 560nM gemcitabine
(PAGR-560C). Acquisition of a resistant phenotype was confirmed with MTT
viability assays, see figure 4.3. These clones displayed more than 50,000 fold
increased IC50 values as compared to the parental cells.
In order to determine possible resistance mechanisms, we performed
Western blotting for key activators and targets of gemcitabine; RRM1, RRM2
and dCK. All gemcitabine-resistant PANC-1 clones tested (PAGR-COL1,
COL-10 and COL-12) were found to have lost expression of the enzyme
deoxycytidine kinase (dCK), see figure 4.3e. dCK catalyzes the rate-limiting
step in activating the gemcitabine prodrug into its phosphorylated derivatives
(dFdC to dFdCMP). Loss of dCK expression as a mechanism of gemcitabine
resistance has been described previously, and has been found to result
in strong gemcitabine resistance[110]. In normal cells, dCK catalyzes the
conversion of dC to dCMP. However, dCK is a relatively promiscuous enzyme
with little substrate specificity, and as a result dCK is responsible for the
phosphorylation of gemcitabine as well as several other nucleoside analogs.
Since we observed the same resistance mechanism in all clones, PAGR-COL1
was chosen for further detailed studies. PAGR-COL1 cells displayed strong
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cross-resistance with the dCK-dependent nucleoside analog cytarabine, little
cross resistance with 5FU and no cross resistance the RRM2-targeting drug
didox, see figure 4.3b-d. As can be seen in figure 4.1, PAGR-COL1 were found
to be morphologically similar to the parental PANC-1 cells.
Figure 4.4: a) immunofluorescent staining shows that reduced EpCAM
and cytokeratin expression is found in TGFβ treated/EMT-induced PANC-1
cells, whereas EGFR expression was retained, b) loss of EpCAM expression
is detected in gemcitabine resistant PAGR-COL1 cells, c) quantitative flow
cytometry reveals significant loss of EpCAM expression in EMT-induced and
gemcitabine resistant cells, EGFR expression was reduced significantly in
gemcitabine resistant cells but only minimally in EMT-induced cells, d) EpCAM
expression displayed higher variability than EGFR expression in all conditions.
EMT-induction led to increased variability of EpCAM and EGFR expression as
well as higher experiment-to-experiment variability, e) flow cytometry reveals
reduced cytokeratin expression in EMT-induced PANC-1 cells
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EpCAM, EGFR and cytokeratin expression in EMT-induced and
gemcitabine resistant cells
After having defined an EMT-induction protocol for PANC-1 cells and
derived gemcitabine resistant subclones from the same cell population, we
set out to determine the effect of these processes on the expression of
CTC markers. The changes in the expression of EpCAM, EGFR and
cytokeratin in EMT-induced and gemcitabine resistant PAGR-COL1 cells was
determined using immunofluorescence and flow cytometry, see 4.4. We
observe a significant down-regulation of EpCAM, both in cells stimulated
to undergo EMT (PANC-1 EMT+) and cells with acquired resistance to
gemcitabine (PAGR-COL1). Growth-factor restriction (PANC-1 EMT-) was
not observed to significantly change the expression of EpCAM or EGFR. As
expected, we observe down-regulation of cytokeratin in EMT-induced cells,
however, not in PAGR-COL1 cells, see figure 4.4. More cell-to-cell, and
experiment-to-experiment variability was observed for EpCAM relative to
EGFR in all samples, which manifests in an increased EpCAM Coefficient of
Variation (CoV), see figure 4.4. This shows that EpCAM expression is more
variable than EGFR expression within the cell populations, and indicates that
EGFR may be a preferable marker for capture. The CoV also increased from
both EpCAM and EGFR in EMT induced samples relative to non-induced
samples, indicating that the EMT induction increased the heterogeneity of
marker expression in the cell populations.
In summary, these results indicated that TGFβ mediated EMT-induction
recapitulates several of the key phenotypic features observed or hypothesized
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for EMT in CTCs; namely loss of cytokeratin and EpCAM-expression, and
increased heterogeneity of marker expression. As EpCAM and cytokeratin are
widely used to capture and identify CTCs, our results support the notion that
EMT presents a potential problem for CTC isolation and identification. EGFR
expression was significantly reduced in chemoresistant PAGR-COL1 cells but
not in EMT-induced cells.
Immunocapture of EMT-induced and gemcitabine-resistant cells
Having determined what effect EMT-induction and acquired gemcitabine
resistance had on the expression of CTC capture markers EpCAM and EGFR
in PANC-1 cells, we next set out to determine the effect on microfluidic
capture performance. PANC-1 cells, EMT-induced PANC-1 cells or gemcitabine
resistant PAGR-COL1 cells were captured using anti-EpCAM, anti-EGFR or
non-specific antibodies using the microfluidic GEDI platform. The results, see
figure 4.5, show that anti-EpCAM and anti-EGFR immunocapture performed
equally well in naive PANC-1 cells. However, EMT-induction and acquired
chemoresistance resulted in significant loss of EpCAM capture performance.
EGFR capture performance was reduced in EMT-induced cells but performed
equally well in PAGR-COL1 cells as in PANC-1 cells. The loss of EpCAM
expression observed by flow cytometry is thus resulted in as a loss of
anti-EpCAM capture performance in both EMT+ and PAGR-COL1 cells.
However, the loss of EGFR-capture in EMT+ cells is not directly explainable
by considering protein expression levels as EMT+ cells did not display a loss
of median EGFR expression. However, we observed an increased variability of
both EpCAM and EGFR expression in these cells, likely contributing to the loss
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of capture performance.
Figure 4.5: a) EMT-induced PANC1 cells and gemcitabine resistant
PAGR-COL1 cells display significantly reduced anti-EpCAM capture in the
GEDI microdevice, reduced anti-EGFR capture was observed in EMT-induced
cells. Overall EGFR capture performed more robustly than EpCAM capture,
b) immunofluorescent resistance phenotyping by staining for cytokeratin, dCK
and DAPI, c) automated imaging of cells captured on chip allows for CTC
phenotyping
Capture performance is thus not a simple linear function of the level of
expression. There is likely a threshold expression level below which the
adhesive strength generated by antibody-antigen interaction is too weak to
immobilize the cells on the surface of the device microposts under the shear
imposed by the fluid flowing through the device, which is consistent with our
previous findings[104]. The capture performance is thus dependent on the
fraction of cells expressing a capture marker level above this threshold. This
can explain why the significant loss of EGFR expression in PAGR-COL1 cells
does not translate to a significant loss in capture performance despite being
on the same relative order as the downregulation of EpCAM in these cells.
anti-EGFR capture performance is retained as the absolute EGFR expression
level remains high in PAGR-COL1 cells. Other potential explanations include
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changes in the distribution and clustering of EpCAM and EGFR receptors on
the cell surface as a result of growth factor treatment and chemoresistance.
As the loss of dCK expression can be detected using fluorescent staining, see
figure 4.5, it would be possible to perform resistance profiling of captured
CTCs on chip. Using automated imaging and cell phenotyping, discussed in
more detail elsewhere[104][114], we could potentially phenotype captured cells
according to the expression of gemcitabine resistant phenotypes, i.e. reduced
dCK expression, see figure 4.5.
4.5 Conclusions
EMT-associated loss of epithelial markers (EpCAM and cytokeratin) in cancer
cells has important implications for CTC capture modalities that rely on
recognition of these markers for cell isolation and identification. Here, we
found that TGFβ-induced EMT recapitulates several key aspects of EMT
observed in patient CTCs. In particular, we observed loss of EpCAM and
cytokeratin expression. We also found a significant loss of EpCAM expression
in cancer cells with acquired gemcitabine resistance. These changes in protein
expression resulted in loss of anti-EpCAM immunocapture performance. We
also identified anti-EGFR capture as a potentially EMT-robust capture mode.
EGFR was expressed by all pancreatic cancer cells and culture conditions tested.
Future work is necessary to compare the performance of anti-EpCAM and
anti-EGFR CTC capture in clinical pancreatic cancer samples.
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CHAPTER 5
ACQUIRED CHEMORESISTANCE CHANGES CELL-SORTING OF
PANCREATIC CANCER CELLS AND RESULTS IN TUMOR SPHEROID
CHEMOPROTECTION
5.1 Abstract
The acquisition of chemoresistance has been shown to lead to changes in cancer
cell phenotype and behavior. Here we show that the acquisition of resistance
to gemcitabine due to a copy-number amplification of RRM1 in pancreatic
cancer cells leads to dysregulation of cell-cell junctions and actin cytoskeleton
regulation. This results in altered cell-sorting behavior in tumor spheroids and
spheroid chemoprotection.
5.2 Background and Introduction
Although most cancers are thought to be clonal in origin, i.e. stemming
from a single cell, it is now well established that over the course of
carcinogenesis, multiple cellular clones typically emerge giving rise to
significant intratumor heterogeneity as well as heterogeneity between a
primary tumor and metastases. The polyclonality of cancer tumors and
the resulting heterogeneity is thought to contribute to the resistance to
chemotherapy[115][116]. Fully developed pancreatic cancer tumors have been
found to be polyclonal[6] and metastatic pancreatic cancer has been shown to
display persistent genomic instability, sometimes resulting in the emergence of
multiple metastasis-competent clones in the same patient[117] or mouse[118].
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Research has also shown that pancreatic tumors are composed of multiple
cellular subpopulations. A small subpopulation of pancreatic tumor cells have
been found to display cancer stem cell characteristics, including ability to seed
metastasis and high intrinsic resistance to chemotherapy[119][120][121]. These
cells have in some cases been observed to localize towards the invasive edge of
pancreatic cancer tumors[120]. Pancreatic cancers are characterized by having
a significant stromal component[5] but relatively little vascularization and
invasion of immune cells. Histologically, pancreatic tumors typically appear
as tumors where ”regions of duct-like epithelium are interspersed with less
differentiated epithelial cells contained within a sea of proliferative stroma”[5].
Pancreatic tumors should thus be regarded as complex tissues, where multiple
cell populations are interacting.
The emergence of the structural components of tissues, and the organization
of cells into layers and domains has been studied extensively in the context
of embryogenesis[122][123][124]. Although the structure of cancer tumors is
thought to arise partially as a result of loss of tissue structure and organization,
the same rules that guide tissue organization in embryogenesis have to be
assumed to apply to tumors. It as been observed that in many cases when
different populations of cells are mixed, domains preferentially containing
only one of the cell populations spontaneously emerge, a result of a process
referred to as ”cell-sorting”. Cell-sorting is a widely observed physiological
processes, such as embryogenesis[122][123][124], pathological processes, such
as the formation of cancer tumors, as well as in in vitro tissue engineering
systems[125][126]. The spontaneous organization of mixtures of two cell
populations into core-shell type aggregates, where one cell type dominates in
the core and the other dominates the shell have been observed in a variety
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of contexts[125][126]. What governs cell-sorting behavior is still debated
and a number of hypotheses have been put forward, most prominently the
differential adhesion hypothesis[125][122][124]. Although no hypothesis has
so far been able to fully explain all types of sorting behavior observed, there
appears to be a consensus that cell-sorting is driven by the differences in
cell-cell adhesion, actomycin contractility and how cellular adhesions link to
the cytoskeleton[124][125]. The theoretical models of cell-sorting often assume
that, like molecules in a Newtonian fluid, the cells are able to sample enough of
the global energy landscape to find an organization that minimizes to total free
energy of the system[125]. In real systems this cannot be assumed to be true,
and non-equilibrium processes, such as jamming[127] likely plays a significant
role in determining the final structure of many cellular systems.
Considering the increasing appreciation for the cross-talk between
regulation of cell-cell junctions and remodeling of the cytoskeleton[128], in
part mediated by Rho-family small GTPases[129][130], it is not surprising that
cell-cell adhesion and contractility both appear to play a role in governing
cell-sorting behavior. Interestingly, the difference in expression of cadherins,
key mediators of cell-cell adhesions in tissues[124], and differences in adhesive
strength were recently shown to not predict the final cell-sorting state of
breast cancer co-cultures of cells spanning the range from epithelial- to
mesenchymal-like cancer cells[125]. These observations also support the idea
that if cell-cell adhesions are dysregulated between two cell populations it can
lead to mechanical polarization of cells and increased tension along the borders
between the cell types[124][125].
One process that is known to in some case profoundly change the
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phenotype of cancer cells is the development of chemoresistance. The
acquisition of resistance to the nucleoside analog gemcitabine (difluoro
deoxycytidine, dFdC), for example, has been shown to result in dramatically
altered cellular phenotypes of cancer cells in vitro, often with development
of EMT-like characteristics such as increased migratory and invasive cellular
behavior[25][26][27]. As a major target of gemcitabine cytotoxic activity,
the ribonucleotide reductase (RNR) subunit RRM1, has been associated with
the development of chemoresistance. Over-expression of RRM1 has been
linked to resistance to gemcitabine chemotherapy both in vitro[131][132] and in
patients[133]. Interestingly, RRM1 expression is associated with longer survival
in cancer patients, presumably due to its role as a tumor suppressor, however
it is a predictive biomarker of poor response to gemcitabine treatment[133].
RRM1 over-expression may thus act as mediator of chemoresistance specific to
the context of gemcitabine therapy. Gemcitabine (dFdC) inactivates RNR by
reacting with the active site of an RRM1 protein in an active RNR complex.
The reaction results in the covalent bond between the ribose sugar of dFdC
to the active site of RRM1, making dFdC an irreversible suicide inhibitor of
RNR. There is evidence that the presence of an excess of RRM1 can result in the
reactivation of RNR[134], and that the accumulation of inactivated RRM1 can
be detected in cells by western blotting[135].
Here we show that the acquisition of resistance to the small molecule drug
gemcitabine in pancreatic cancer cells is caused by a copy-number amplification
of the resistance-mediating protein RRM1 and results in a phenotypic switch
that changes the cell-sorting behavior of drug-resistant and sensitive cells when
grown in spheroid co-cultures. The preferential localization of resistant cells to
the surface of spheroids, in combination with the over-expression of RRM1 in
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the resistant cells, results in chemoprotection of co-culture spheroids.
5.3 Materials and Methods
Cell culture
BxPC-3 and PANC-1 cells were obtained from ATCC (Manassas, VA). Cell
lines were cultured in a humidified incubator (37 ◦C and 5% CO2) using media
recommended by ATCC (BxPC-3: 10% FBS RPMI and PANC-1: 10% FBS
DMEM) with 100 units penicillin, 0.10 mg streptomycin and 0.25 g amphotericin
B per ml (Sigma).
Western blotting
Cells were seeded at 500,000 cells/60mm in tissue culture treated dishes, 48h
prior to harvest of protein lysates. Before lysis, cells were washed with
ice-cold PBS followed by complete removal of the supernatant. 100ul lysis
buffer (50 mM Tris, 1% (v/v) Triton X-100, 150 mM NaCl, 2mM PMSF, 1mM
sodium orthovanadate and 1X protease inhibitor cocktail from Santa Cruz
Biotechnology) was then added per plate. Cells were lysed by mechanical
disruption using a cell scraper. Lysates were pipetted 10 times with a 1000ul
pipettor to homogenize. Insoluble cellular components were removed by
spinning the raw lysates at 15,000xg, for 9 minutes at 4◦C. The lysates were then
frozen down at -80◦C or used right away. Following protein quantification with
the DC protein assay (Bio-Rad), lysates were heat-treated in Laemmli sample
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buffer (2% SDS, 2% 2-mercaptoethanol, 0.1% bromophenol blue, 10% glycerol,
62.5 mM Tris-HCl) in a dry bath set to 98◦C for 5 minutes. 10-15 ug total
protein per well was then loaded in 4-20% Tris-Glycine gradient polyacrylamide
gels (Thermo). The Bio-Rad Kaleidoscope protein ladder was used as positive
control. SDS-PAGE ran at 160V on ice for approximately 1h and 30min in
running buffer (25 mM Tris-HCl, 190 mM glycine, 0.1% SDS). Proteins were then
transferred to 0.45µm PVDF blotting membranes (Millipore) by electrophoresis
at 400mA for 1h and 45min in transfer buffer (25 mM Tris-HCl, 190 mM
glycine, 0.1% SDS, 20% methanol) with constant water cooling. Following
protein blotting, the membranes were washed in TBST buffer (20 mM Tris-HCl,
150 mM NaCl, 0.1% (v/v) Tween 20) and blocked for 2h in 3% BSA (w/v)
in TBST. Blots were stained with primary antibodies over night at 4◦C with
constant rocking. Primary antibodies used: anti-RRM1 (EPR8483, abcam),
anti-RRM2 (N1C1, GeneTex), anti-RRM2B (AF3788, R&D Systems), anti-dCK
(Bethyl), anti-E-cadherin (24E10, CST), anti-STIM1 (Bethyl), anti-RhoG (1F3 B3
E5, Biolegend), anti-β-actin (D6A8, abcam). Following washing, the membranes
were stained with HRP-conjugated secondary antibodies for 1h at room
temperature. Blots were developed with Western Lightning Plus Enhanced
Chemiluminescence Substrate (Perkin Elmer) and imaged on a Chemigenius
bio-imager.
MTT cytotoxicity assay
For determining the IC50 values for gemcitabine and other drugs using
MTT cytotoxcity assays, cells were first seeded at 500,000 cells per 60mm
dish. After 48 hours of culture, cells were trypsinized and seeded at
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5,000 cells per well in 200ul complete media in 96-well plates. Cells
were allowed to adhere over-night and media was then replaced with
150ul/well of a 11-point dilution curve of each drug in complete media with
6 replicate wells per condition, including untreated cells and media-only
controls. After 96 hours of culture, 16ul of 5mg/ml sterile filtered MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Affymetrix)
was added per well. Plates were incubated for 4 hours to allow for the cells to
metabolize MTT into purple formazan crystals. Plates were then centrifuged
at 1000xg for 5 min to pack formazan crystals on the well bottom. Media
was removed by inverting the plates and was replaced by 200ul of acidified
isopropanol (50mM HCl and 0.1% Triton X-100 in isopropanol). The solution
was pipetted up and down vigorously to dissolve formazan crystals, and plates
were left on an orbital shaker set for 37C for 15 min, plates were then inspected
for poorly mixed wells. Plates were then read at 560nm and 690nm using a
plate reader (Biotek). The relative viability of each drug concentration was
calculated by subtracting absorbance at 690nm from 560nm, normalizing to
the untreated wells, and averaging the 6 replicates. Sigmoidal kill-curves were
fitted to the MTT data using Matlab and IC50-values were calculated as were the
interpolating function crosses 50% relative viability.
qPCR copy-number amplification assay
DNA was isolated from pellets containing one million cells for each biological
replicate using a DNA micro kit (Qiagen), following the supplier protocol,
with the addition of an RNase A treatment step. Isolated DNA was stored
at -80C prior to copy-number analysis. Immortalized HUVEC E4 cells were
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included in the experiment as a diploid control. A predesigned TaqMan RRM1
qPCR CNV assay (Hs02671698cn, Thermo) was used with an TaqMan RNseP
qPCR CNV internal reference assay (Thermo). Copy-number analysis was
performed using a ViiA 7 qPCR machine, following the suppliers instructions.
Each sample was analyzed with three technical replicates per analysis and each
analysis was repeated three times (three biological replicates). To determine
the RRM1 copy-number for each cell line and sub-clone, the Ct value for each
sample and assay was extracted from the amplification plots. A ∆Ct value
was determined for each sample (∆Ct = CtRRM1-CtRNaseP), and by assuming
exponential amplification, a relative copy-number was then calculated from
the ∆Ct-value (nrel=2−∆Ct). An absolute copy-number was calculated by
normalizing to the HUVEC diploid control (nabs,subcloneX=nrel,subcloneX/nrel,HUVEC*2).
The amplification plots were consistent with a diploid copy-number of 2 for
RNseP in all samples, indicating that it is an appropriate control for the assay.
siRNA knock-down
For siRNA-mediated knock-down cells were seeded at 400,000 cells/6-well and
allowed to adhere over-night. Media was then replaced with 2ml complete
media. Cells were then transfected with 125pmol siRNA per 1e6 cells using
Lipofectamine RNAiMAX (Thermo). For Western blotting the cells were
allowed to incubate with the transfection agent for 72 hours, followed by
lysis and Western blotting with the standard procedure described above.
Pre-designed Steath siRNAs (Thermo) were used for knock-down: RRM1
(HSS109388, 5’-AAGAUCUGCUUAUUCAGUAACUGGG-3’).
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Immunofluorescence
Cells were seeded in tissue-culture treated optical-bottom 96-well plates
(Thermo) and allowed to grow for 24 hours. Following washing with PBS,
cells were fixed with 2% formaldehyde in a PBS/PHEM buffer (60 mM
PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2) for 15 minutes. Cells
were then blocked with 10% normal goat serum for 45 minutes, followed by
permeabilization with 0.1% saponin for 5 minutes, when necessary. Following
permeabilization, cells were incubated with primary antibodies overnight
at 4◦C: anti-N-cadherin (R&D Systems), anti-vimentin (RV202, Santa Cruz
Biotechnology), anti-E-cadherin (24E10, CST). Cells were then incubated with
Alexa Fluor 488, 568 or 647-conjugated secondary antibodies (Life Technologies,
Grand Island, NY) for 1 hr at room temperature. For phalloidin staining,
cells were incubated with phalloidin conjugated to CruzFluor488 (Santa Cruz
Biotechnology, Santa Cruz, CA). Cells were then counterstained with 1ug/ml
DAPI (Sigma-Aldrich, St. Louis, MO) for 15 minutes. Representative images
were then acquired using a Nikon Eclipse TE2000-U fluorescent microscope or
using a Zeiss i880 confocal/multiphoton microscope.
Attachment-free spheroid cell culture
1.5% (w/v) agarose was dissolved in deionized water by heating on a hot plate
with constant stirring. When the agarose is completely dissolved, the solution
was sterilized by autoclaving at 121◦C for 25 minutes. Sterile agaose was then
aliquoted and stored at 4◦C for later use. To create cell-attachment-free wells,
agaose was re-melted by placing the tubes in boiling water until completely
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melted. 50ul melted agarose was then pipetted into sterile 96-well plates and
plates were swirled to ensure even coverage of the well bottoms. Agarose
was allowed to cool down and solidify to at least 30 minutes before adding
cells. When solidified, 100ul cell-containing media was then added per well.
A total of 2,000 cells were used per spheroid. When appropriate 5µM of the
store operated calcium entry inhibitor SKF96365, or 5µM of the Rac1 inhibitor
EHop-016 was added.
Spheroid viability assay
48h-old spheroids were treated for 6 days in complete media with or without
gemcitabine. Spheroids were labeled by adding propidium iodide and
Calcein-AM in serum-free RPMI to spheroid-containing 96-wells. Spheroids
were incubated for 30 min and then placed on ice for 10 min, before imaging
using a Nikon Eclipse TE2000-U fluorescent microscope.
Multiphoton microscopy
Cells were seeded in complete media at 100,000 cells/24-well and were allowed
to adhere over-night. The supernatant was replaced with either CellTracker
Green or CellTracker Red (Thermo) at 10µM in serum-free RPMI, and was
allowed to incubate with cells for 30 min. After washing with complete media,
spheroids were seeded normally. Spheroids were imaged on using a Zeiss i880
confocal/multiphoton microscope.
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Spheroid cryosectioning and immunofluorescent staining
For cryosectioning spheroids were collected and allowed to settle in
microcentrifuge tubes on ice. Following washing with ice cold PBS,
spheroids were fixed in 4% formaldehyde in a PBS/PHEM buffer (60 mM
PIPES, 25 mM HEPES, 10 mM EGTA, 2 mM MgCl2 ) for 20 minutes.
Spheroids were stained with 1% methylene blue to make spheroids visible
when cryosectioning. Methylene blue-stained spheroids were embedded in
Tissue-Tek O.C.T Compound and flash frozen in liquid nitrogen. Spheroids
were stored for a minimum of 48h in -80◦C before cutting. 8µm spheroid
sections were cut onto glass slides. Following removal of embedding matrix by
dipping in deionized water and PBS, slides were stained following the standard
immunofluorescence protocol described above.
5.4 Results and Discussion
Pancreatic cancer cells with acquired resistance to gemcitabine
over-express RRM1
To investigate the relationship between cancer cell phenotype and acquisition
of chemoresistance, we first generated gemcitabine-resistant subclones derived
from the human pancreatic cancer cell line BxPC-3. The subclones were
generated by exposing BxPC-3 cells to increasing concentrations of gemcitabine
over a 10-month period. Cell treatment was started at 16nM, as this
concentration had been determined to be just below the 96-hour gemcitabine
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IC50 value for the parental BxPC-3 cells. Transiently increased resistance
was observed in the cultures up to about 90nM, where treatment resulted in
complete loss of viability. By treating multiple flasks at 80nM we were able
to generate a resistant sub-clone emerging from one of the flasks. This clone,
referred to as BxGR-80C (for BxPC-3 Gemcitabine Resistant, 80nM, Constant
exposure) was isolated and subculured for further experiments. A second
resistant clone (BxGR-360C) was isolated from BxGR-80C cells treated with
360nM gemcitabine, following near complete loss of viability in the treated
flasks. The gemcitabine resistance of these clones was observed to be stable,
as the cells retained resistance after having been grown without gemcitabine for
more than 20 passages.
Figure 5.1: a) phase contrast imaging of the pancreatic cancer cell line
BxPC-3 and the gemcitabine resistant sub-clones BxGR-80C and BxGR-360C,
b) BxGR-360C cells display decrease proliferation rate as compared to BxPC-3
and BxGR-80C cells, doubling times were estimated to be approximately 24h for
BxPC-3 and BxGR-80C and 30h for BxGR-360C
The gemcitabine IC50-values (96h treatment) were determined to be
approximately 11nM, 200nM (18-fold increase) and 3300 nM (200-fold increase),
for BxPC-3, BxGR-80C and BxGR-360C cells respectively, see figure 5.2a. The
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Figure 5.2: a) BxGR-80C and BxGR-360C display significantly increased
resistance to gemcitabine as indicated by increased IC50 values compared to
BxPC-3 cells, b) no doxorubicin cross-resistance was observed in gemcitabine
resistant cell lines, c) some cross resistance was observed with 5FU, d) no
significant didox cross-resistance was observed, e) Western blotting analysis
reveal upregulation of RRM1 in gemcitabine resistant BxPC-3-derived cell lines
BxGR-80C and BxGR-360C, no significant changes in RRM2, RRM2B or dCK
expression was observed
BxPC-3 and BxGR-80C cells were observed to display similar morphologies
and growth behavior in standard 2D culture, including the formation of
distinct epithelial colonies in culture, see figure 5.1.BxGR-360C cells were
observed to display a more fibroblast-like morphology, with less pronounced
colony-formation and a slightly slower growth rate.
To determine potential resistance mechanisms, we measured the expression
of known gemcitabine resistance mediators and major targets of gemcitabine,
using Western blotting, see figure 5.2e. This protein panel consisted of RNR
subunits RRM1, RRM2 and RRM2B, as well as the key gemcitabine-activating
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enzyme deoxycytidine kinase (dCK). Using this approach, we found that the
BxPC-3-derived sub-clones over-express RRM1. The expression of the other
proteins assayed were all unchanged. Using quantitative Western blotting we
determined the over-expression of RRM1 to be approximately 20 and 120-fold,
in BxGR-80C and BxGR-360C cells, respectively, see figure 5.3b.
To further characterize the resistance of BxGR-80C and BxGR-360C we
tested their cross-resistance with other mechanistically related or unrelated
small molecule inhibitors. The results of these studies were consistent
with an RRM1-mediated resistance mechanism as gemcitabine resistant cells
displayed increased resistance to the RRM1-targeting drug clofarabine, but
to not to the RRM2-targeting drug didox or to the DNA-targeting drug
doxorubicin, see figure 5.2. Interestingly, we observed some cross-resistance
with 5-FU. BxGR-360C but not BxGR-80C cells displayed cross-resistance with
the structurally similar, but RNR non-targeting drug cytarabine.
Copy-number amplification of RRM1 has been reported to be responsible
for RRM1 over-expression in gemcitabine resistant cells. Using qPCR,
we determined BxGR-80C and BxGR-360C to have accumulated RRM1
copy-number amplifications of approximately 10- and 60-fold, respectively. The
modal RRM1 copy-number of BxPC-3 was determined to be 1, see figure 5.3c.
The RRM1 over-expression thus correlated directly with the observed
copy-number amplification in the respective cells, indicating that the
amplification likely is a direct cause of the protein over-expression.
Furthermore, the gemcitabine IC50-values were observed to correlate directly
with RRM1 protein expression and copy-number, indicating that the level
of resistance is directly proportional to the amount of RRM1 present in the
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Figure 5.3: a) BxGR-80C and BxGR-360C display 20- and 300-fold increased
gemcitabine IC50-values as compared to BxPC-3 cells, respectively, as
determined by MTT cytotoxicity assays b) BxGR-80C and BxGR-360C display
20- and 120-fold RRM1 protein expression as compared to BxPC-3 cells,
respectively, as determined by quantitative Western blotting c) BxPC-3,
BxGR-80C and BxGR-360C cells were determined to have modal RRM1
copy-numbers of 1, 11 and 61, respectively, as determine by qPCR CNV analysis
cells. We therefore conclude that at least two events leading to copy-number
amplification of the region of chromosome 11 containing the gene encoding the
RRM1 protein have occurred in the BxPC-3 cells, giving rise to the BxGR-80C
and BxGR-360C sub-clones respectively.
RRM1 over-expression leads to gemcitabine resistance
To functionally test if RRM1 over-expression is responsible for the observed
gemcitabine resistance, we performed siRNA mediated knockdown of RRM1
in BxGR-360C. siRNA knock-down resulted in dramatic resensitization of
BxGR-360C cells, see figure 5.4. Following about 40% knock-down of RRM1,
as estimated from Western blotting, the gemcitabine IC50 value was decreased
by 90% in BxGR-360C cells, indicating significant loss of gemcitabine resistance.
Over-expression of RRM1 directly leading to acquisition of gemcitabine
84
Figure 5.4: a) western blotting of untreated, RRM1 siRNA-treated and
control siRNA-treated BxGR-360C cells reveals partial RRM1 knock-down,
b) knock-down of RRM1 using siRNA interference results in significant
sensitization of BxGR-360C cell to gemcitabine, RRM1 and control
siRNA-treated BxGR-360C cells display gemcitabine IC50 values of 0.26
and 2.68µM, respectively
resistant is consistent with previous knowledge. The diphosphorylated
metabolite of gemcitabine (dFdCDP) is known to inhibit RNR by reacting with
the assembled and active RNR complex, forming a covalent bond between
the sugar of gemcitabine and the RRM1 subunit of RNR[134]. Although, the
inactivated RNR-complex is thought to be stabilizedin vitro, results support the
idea that the presence of an excess of RRM1 can lead to the reactivating of RNR,
presumably by functional RRM1 replacing inactivated RRM1 (RRM1*) in the
RNR complexes[134].
RNR is an evolutionarily conserved enzyme complex that controls the
balance of NDPs and dNDPs in all living cells[134]. Aberrantly low or high
levels of RNR activity would likely lead to loss of cell viability as a disrupted
NDP/dNDP balance would have severe consequences for a cell. In healthy
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cells, RNR activity is primarily controlled by the expression level of RRM2,
which is highest during S phase[136]. As we observed the expression of RRM2
to be unchanged in the RRM1-overexpressing sub-clones and as the level of
RNR activity is primarily determined by the level of RRM2 present, the excess of
RRM1 will thus likely not disturb the NDP/dNDP balance in the cells. Despite
observing a 120 fold increase in the amount of RRM1 in our BxGR-360C cells,
we only observe a moderately decreased growth-rate. It has previously been
described that the reaction of dFdCDP in vitro and in vivo leads to the formation
of an inactivated form of RRM1 (RRM1*)[134][135] with an apparent molecular
mass of about 110-120kDa, rather than the normal 90kDa, when analyzed by
western blotting[135].
Figure 5.5: Western blotting reveals dose-dependent response to gemcitabine
treatment in BxPC-3, BxGR-80C and BxGR-360C. Dose-dependent induction
of a RRM1 conformation migrating as an approximately 120kDa protein was
observed in gemcitabine treated cells, the intensity of this band was observed
to reach a maximum at concentrations around the gemcitabine IC50-value for
each cell line. Induction of RRM2 expression was observed at gemcitabine
concentrations around the IC50-value for each cell line
In our resistant cells, we observe a dose-dependent induction of a higher
molecular weight RRM1 band with an apparent mass of about 120kDa in cell
treated with gemcitabine, see figure 5.5. Furthermore, we observe that the ratio
between the higher and lower molecular weight RRM1 bands correlates with
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the observed IC50 values of the respective cell lines. Specifically, the higher
molecular weight RRM1 band increases in intensity up until a gemcitabine
concentration that correspond to the IC50 concentration of the respective
cell lines is reached. At gemcitabine concentrations above the approximate
IC50 value, the band intensity appears unchanged, indicating a maximum
accumulation of RRM1*. This observation strengthens our hypothesis that the
observed gemcitabine resistance in these cells is a direct result of a presence of
excess RRM1, as the saturation value of the ratio between the RRM1* and RRM1
bands likely represents a state where the cells have exhausted their stores of
excess RRM1. RRM1 upregulation thus likely leads to gemcitabine resistance
by two mechanisms, the presence of excess RRM1 allows cells to (1) maintain
enough RNR activity to sustain cell viability despite dFdCDP mediated
inactivation of RRM1 by switching out inactivated with functional RRM1,
and (2) detoxify gemcitabine by providing enough RRM1 for it to react with,
reducing the amount of free and active gemcitabine. In addition, we observe
induction of RRM2 expression when the cells are exposed to gemcitabine
concentrations above the IC50-value, likely a result of an accumulation of cells
in S-phase or a compensatory upregulation of RRM2, in response to lack of
RNR-activity.
Gemcitabine resistant cells display evidence of cell-cell junction
and cytoskeleton dysregulation
From other studies we know that the acquisition of gemcitabine resistance in
pancreatic cancer cells has been linked with an upregulation of mesenchymal
markers and the development of an EMT-like phenotype[25][26][27]. As we
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observe a markedly altered morphology in BxGR-360C cultures, these initial
observations appear to support these findings. To characterize the EMT and
cytoskeletal phenotypes of the resistant cells, we performed immunofluorescent
staining, in some cases followed up by western blotting for markers involved in
these processes. Our results show that BxGR-360C cells express a higher level
of filamentous vimentin, a mesenchymal intermediate filament, as compared to
parental BxPC-3 cells, see figure 5.6c. No significant difference was observed for
the EMT-marker N-cadherin in these cells. BxGR-360C cells were observed to
form fewer E-cadherin cell-cell junctions as compared to BxGR-80C and BxPC-3
cells, however, the total amount of E-cadherin present in the cells was observed
to be the same for all three cell lines in western blotting, see figure 5.6a and
b. BxPC-3 and BxGR-80C cells displayed similar phalloidin staining patterns,
whereas BxGR-360C showed a markedly altered intracellular actin distribution
and structure. BxGR-360C cells were found to display markedly increased
number and size of lamellipodia and cell membrane-associated actin filament
formation, as judged by phalloidin staining, see figure 5.6a. BxGR-80C show
evidence of somewhat increased filamentous actin expression as compared to
BxPC-3 cells, but the difference was subtle. Overall, the resistant cells display
evidence of dysregulation of adherens-junction and actin cytoskeleton, most
pronounced in the BxGR-360C cells.
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Figure 5.6: Gemcitabine resistant cells display evidence of cell-cell junction
and cytoskeletal dysregulation, a) BxGR-360C cells display remodeled actin
cytoskeleton, including increased lamellipodia formation (white arrow), and
loss of E-cadherin localization to cell-cell junctions (yellow arrow), b)
western blotting reveals similar expression of E-cadherin in all sub-clones but
over-expression of STIM1 and RhoG associated with a genetic amplification
in the chromosome 11p15.4 genomic region, c) BxGR-360C display increased
filamentous vimentin (white arrow) expression as compared to BxPC-3 cells
Gemcitabine resistant cells over-express proteins associated
with a RRM1 copy-number amplification of a region of
chromosome 11p15.4
As discussed previously, we determined the RRM1 over-expression to
result from a copy-number amplification of the RRM1 gene, located in the
chromosome 11p15.4 region in the human genome. To determine if other genes
in this genomic region were also over-expressed in these cells, we performed
western blotting for the RhoG and STIM1 proteins, located within 300kb of the
RRM1 start codon. The 3’ end of the STIM1 gene is located in a head-to-tail
configuration only 1.6 kb from the 5’ end of the RRM1, whereas the RhoG is
located 270 kb upstream of the RRM1 gene, on the complimentary DNA strand.
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Both proteins were observed to display the same pattern of over-expression
in the resistant cells as RRM1, see figure 5.6b. These results strengthen
the conclusion that the RRM1 over-expression results from a copy-number
amplification and offers an explanation of the alterations in cell phenotype
observed as potentially being caused by passenger amplifications of genes
functionally unrelated to RRM1 but located in the same genetic region. This
result may thus also explain observations of altered phenotype in gemcitabine
resistant subclones of BxPC-3 cell made by others[25][26][27]. The discrepancy
of phenotypic alterations observed to result from gemcitabine resistance in
different pancreatic cancer cell lines may thus be a result of alternative resistance
mechanisms being driven by different genetic alterations (RRM1 copy-number
amplification, dCK deletion). However, it is remarkable that the acquisition of
a more migratory phenotype has repeatedly been observed, in our work and in
the work by others.
RhoG is a small GTPase in the Rho family, with significant structural
similarity with Rac1[137]. The role of RhoG in healthy and cancerous
cells is still debated as early results indicated RhoG as major regulator
of Rac1 localization and activity[138][139], however, this observation has
been challenged by several newer studies[140]. However, RhoG does
appear to play a part in the regulation of actin cytoskeleton cell membrane
structure[141][142][143][144], and has been linked to cell migration and
invasion[145][146]. STIM1 is a major component of the regulatory part of
store operated calcium entry (SOCE) and functions as a endoplasmatic sensor
of Ca2+, and signals to its calcium channel partner Orai when the ER is
depleted of Ca2+. STIM1 signaling results in the assembly and opening of
Orai calcium channels and calcium entry into the cytoplasm[147]. STIM1
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has also been linked to migration[148][149][150][151][152], contractility[151],
invadopodia formation[148] and metastasis[152].
Rac1 inhibition during spheroid formation was observed to prevent
cell-sorting and negatively effect spheroid formation while no effect was
observed from SOCE inhibition, see figure 5.10b.
Resistant sub-clones retain ability to form tumor spheroids in
attachment-free culture
The phenotypic alterations observed as result of gemcitabine resistance
observed by us and others, spurred us to inquire what potential effect these
alterations would have on the behavior of gemcitabine resistant cells grown
in 3D tumor models as opposed conventional 2D cell culture on rigid plastic
substrates. Using an attachment-free culture method we found that the resistant
cells retained the ability to form tumor microspheroids, see figure 5.7a. In
contrast, the mixed epithelial/mesenchymal phenotype cell line PANC-1 was
unable to form spheroids under the same conditions. Spheroid formation
was typically observed within 24 hours of seeding cells and spheroids were
observed to contract somewhat over-time, see figure 5.7b. No significant
spheroid growth, as measured by spheroid diameter was observed over time in
attachment free cultures. However, significant spheroids growth was observed
when spheroids were encapsulated in matrigel (data not show).
As can be seen in figure 5.7c, the level of gemcitabine resistance, as
determined by calcein/propidium iodide staining in gemcitabine treated
spheroids was observed to be greatly increased in 3D culture as compared
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Figure 5.7: a) all BxPC-3-derived cells retain the ability to form tumor spheroids
in attachment-free culture, whereas PANC-1 cell do not, scale bar 100µm, b) no
signifcant growth is observed in spheroids after initial formation and spheroids
are observed to contract over time, c) estimation of spheroid resistance to
gemcitabine using calcein and propidium iodide to label live and dead cells,
respectively, BxGR-360C cells appear to tolerate gemcitabine 50-fold higher than
the 2D IC50 value when cultured as tumor spheroids
to conventional 2D culture, consistent with previous literature. We attribute
this effect to be the result of the decreased cellular growth-rate observed in 3D
culture and the limited drug mass transport into the spheroids.
Resistant cells preferentially localize the outer layer of spheroid
co-cultures
To look at the internal cellular structure of heterogenous tumor spheroids we
generated co-culture spheroids by mixing BxPC-3 and BxGR-360C cells. Using
multiphoton microscopy (MPM) we were able to image the entire cross-section
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Figure 5.8: a) (top) within 4 hours of seeding cells, a lose network of mixed
gemcitabine resistant (BxGR-360C) and sensitive cells (BxPC-3) forms, (bottom)
at 28 hours the cellular network has contracted into a spheroid with the resistant
cells localized to the surface, b) preferential surface localization of resistant cells
is observed in spheroid culture, cells were labeled with CellTracker Green or
Red prior to seeding spheroids and were imaged using multiphoton microscopy
after 48h of culture
of approximately 200um diameter co-culture spheroids, consisting of a total of
2000 cells without much of the signal drop-off observed for confocal microscopy.
Within 30-hours of seeding the spheroids, we observe a striking preferential
localization of the BxGR-360C cells to the outer layer of the formed spheroids,
see figure 5.8. In these spheroids, gemcitabine-sensitive BxPC-3 cells form a
core, surrounded by a layer of BxGR-360C cells. The thickness of the layer of
resistant cells was observed to correspond directly to the fraction of resistant
cells in the co-cultures. Near-complete surface coverage of resistant cells was
observed then the resistance cells constitute 25% or higher of cells in spheroids
consisting of a total of 2000 cells. These results were consistent between live cell
MPM imaging and cryosectioning followed by immunofluroescence, see figure
5.9b.
93
Figure 5.9: a) preferential surface localization of gemcitabine resistant
cells (BxGR-360C) when cultured in spheroids with sensitive cell (BxPC-3)
is observed across co-culture ratios, b) cryosectioning followed by
immunofluorescent staining for RRM1 (green) reveals surface localization
of BxGR-360C cells in spheroids, 8µm thick section, DAPI (blue), cytokeratin
(red)
We next sought to determine if the cell-sorting behavior was consistent
across both resistant sub-clones. To this end we generated co-culture spheroids
with all permutations of BxPC-3, mixed together in pairs, see figure 5.10a.
To our initial surprise, we found that both resistant sub-clones preferentially
localize to the spheroid surface, but that no cell-sorting occurs between 80C
and 360C cells. This is surprising as BxPC-3 and BxGR-80C cells are almost
phenotypically indistinguishable, whereas BxGR-360C display a very different
phenotype, as discussed a section above. To rule out any effect of seeding
order or difference in cell settling due to presence of cell clumps we performed
experiments with filtered cells and reversed the seeding order, neither of which
changed the preferential localization of resistant cells to the surface.
To look closer at the dynamics of spheroid formation, we also performed
MPM time-lapse studies on these spheroids, see figure 5.11. These studies
indicate that a loosely associated, mostly flat, network of cells forms within 4
hours of seeding the spheroids and that spheroid formation results from the
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Figure 5.10: Multiphoton live-cell imaging of heterogeneous co-culture
spheroids. a) Gemcitabine resistant cells BxGR-80C and BxGR-360C display
preferential surface localization when co-cultured with drug-sensitive BxPC-3
cells. No cell-sorting is observed between resistant cells or in spheroids
consisting of only one cell type, b) (top) representative spheroid of untreated
resistant and non-resistant cells, (middle) Rac inhibition was observed
to prevent cell-sorting and adversely affect spheroid formation, (bottom)
inhibition of store operated calcium entry (SOCE) was observed to not effect
cell-sorting, scale bar 100µm
relatively rapid contraction of this cellular network. By looking in detail at the
position of resistant BxGR-360C cells over-time reveals that the BxPC-3 cells
contract to form the core of the spheroids, and during this process a majority of
resistant cell are deposited on the spheroid surface.
Gemcitabine resistant cells exert a chemoprotective effect on
spheroid co-cultures
As discussed previously, the upregulation of RRM1 in BxGR-360C cells results
in gemcitabine detoxification by supplying and excess of RRM1 for gemcitabine
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Figure 5.11: Live-cell time lapse multiphoton imaging of spheroid formation.
1500 gemcitabine sensitive BxPC-3 cells (green) were seeded with 500
gemcitabine-resistant BxGR-360C cells (red) in attachment free wells, time lapse
imaging was started after 8 hours and spheroids were imaged every 30 minutes
for 8 hours, complete spheroid formation was observed after 24 hours, a focal
plane near the spheroid center is shown, scale bar 100µm
to react with. The presence of RRM1 over-expressing cells in a tumor
may thus lead to gemcitabine depletion in the tumor microenvironment,
potentially protecting not only the RRM1 over-expressing cells but also cells
in the surrounding microenvironment. Given that the RRM1 over-expressing
BxGR-360C cells preferentially localize to the spheroid surface when co-cultured
with gemcitabine sensitive BxPC-3 cells, it is possible that the resistant cells
may exert a chemoprotective effect on the spheroid as a whole. To determine
if this is the case, we exposed co-cultured spheroids consisting of varying ratios
of resistant and sensitive cells to a range of gemcitabine concentrations. The
relative fraction of viable and dead cells was then determined.
Figure 5.12a shows that here is a marked protective effect from having a
small fraction of BxGR-360C cells mixed into a population of BxPC-3. This
effect is readily observable when the fraction of resistant cells is 25% or higher,
the cellular fraction above which complete surface coverage of resistant cells is
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Figure 5.12: Live/dead labeling reveals a chemoprotective effect of gemcitabine
resistant cells on heterogenous tumor spheroids treated with gemcitabine.
a) a marked chemoprotective effect is observed when a small fraction of
gemcitabine-resistant BxGR-360C are co-cultured with drug-sensitive BxPC-3
cell in the presence of gemcitabine, b) the protective effect is lost when RRM1 is
knocked-down using siRNA interference in BxGR-360C cells, calcein labels live
cells (green) and propidium iodide labels dead cells (red)
observed. Importantly, this protective effect was abolished when RRM1 was
knocked down in the resistant cells prior to spheroid formation, see figure
5.12b. This observation thus supports the idea that a minority of cancer
cells, expressing a drug resistance pathway may have a positive effect on
the viability of the cancer cell population as a whole. We hypothesize this
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effect results from the depletion of gemcitabine in the local environment by
the RRM1-overexpressing cells, in combination with the limited mass transfer
of gemcitabine into the tumor spheroids. The protective effect could thus be
overcome by increasing the concentration of available gemcitabine, overflowing
the RRM1 resistance mechanism and increasing the flux of drug into the
spheroid.
5.5 Conclusions
In conclusion, this work shows that acquisition of genetic mutations, driven
by the selection for drug resistance, can lead to changes in microscopic cancer
cell phenotype that lead to altered macroscopic properties such as cell-sorting
behavior, resulting in increased cell population-level drug resistance.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS
6.1 Conclusions
6.1.1 Cellular mechanisms of acquired gemcitabine chemoresistance
In our cell line models of acquired resistance to gemcitabine we have
identified two, previously described, independent resistance mechanisms.
Cell line subclones derived from PANC-1 and HPAF-II cells display loss of
deoxycytidine kinase expression, whereas subclones derived from BxPC-3
display copy-number amplification and overexpression of the ribonucleotide
reductase (RNR) subunit RRM1.
Although these resistance mechanisms lead to the same end result, i.e.
increased cellular tolerance to gemcitabine, they are different in principle of
molecular mechanism. Loss deoxycytidine kinase diminishes intracellular
activation of gemcitabine by preventing the phosphorylation of gemcitabine
into gemcitabine monophosphate. Whereas, RRM1 is a subunit in the RNR
enzyme complex that catalyzes the conversion of NDPs to dNDPs, and thereby
supplies building blocks for DNA synthesis. Gemcitabine diphosphate is a
irreversible suicide inhibitor of RNR that inhibits the enzyme by covalently
reacting to RRM1 subunits in enzymatically active RNR complexes. By
overexpressing RRM1, the resistant cells are able to neutralize gemcitabine by
allowing the drug to react with RNR complexes and then presumably replacing
the inactivated RRM1 with active RRM1, which they have in excess.
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Our results indicate that the loss of deoxycytidine expression results
in a stronger induction of chemoresistance to gemcitabine than RRM1
overexpression without affecting cell proliferation and viability in any obvious
way. RRM1 overexpression however, resulted in more moderate resistance
to gemcitabine and significantly slower proliferation rate was observed in
cells expressing very high levels of RRM1 (BxGR-360C cells). Since we have
concluded that there is a stoichiometric relationship between the level of RRM1
overexpression and the ability of the cell to neutralize gemcitabine in these
cells, we would predict that this would lead to a resistance mechanism with
limited maximum efficiency. The cells cannot produce unlimited amounts
of a particular protein to cope with the drug, and very high levels of
overexpression probably have off-target effects. Furthermore, it is thought
that RNR inactivation sometimes leads to inactivation of RRM2 as well as
RRM1, in which case excess RRM1 alone would not be able to rescue RNR
activity. As we have shown conclusively, the genetic amplification also led
to the overexpression of other genes in the vicinity of RRM1 (passenger
amplifications), genes that may have unpredictable or unfavorable results on
cell phenotype and viability when overexpressed.
In this system, it remains unknown why different cell populations under
identical conditions develop different resistance mechanism. However, despite
in some cases isolating several resistant clones form the same cell line, we
always observed the same resistance mechanism emerging in a particular cell
line. It is interesting to note that both PANC-1 and HPAF-II are KRAS mutant
and SMAD4 wild-type, whereas BxPC-3 are KRAS wild-type and SMAD4
mutant. It is thus possible that the genotype of the cells and resulting cellular
state influences the likelihood of a particular resistance mechanism emerging
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in the cell population. It is also possible that whichever mechanism emerges
first, in a purely stochastic way, becomes the dominant resistance mechanism.
Amplification of the RRM1 gene is, to our knowledge, only observed in a
small fraction of pancreatic cancer patients. However, it is possible that RRM1
amplification is especially relevant in the small minority of patients (<10%) that
suffer from KRAS wild-type pancreatic cancer.
It is also important to remember that conventional chemotherapy is
transient. Typically, a patient is treated with a drug through intravenous
administration for a relatively short period of time, with a predetermined
treatment frequency. The treatment dose, infusion rate and frequency is
empirically optimized to maximize the drug efficacy and minimize side effects.
Cancer cells are thus only exposed to the drug for a relative short period
if time. The half-life of gemcitabine in patients ranges from 30 min to 10
hours, depending on length of infusion and patient characteristics, indicating
that the duration of drug-exposure is on the order of hours. This means
that in order for a tumor to become clinically resistant to therapy, the cancer
cells do not necessarily have to develop resistance mechanisms that allow
them to proliferate in the presence of a constant drug concentration. The
cells only have to avoid accumulating enough cytotoxic damage to trigger cell
death while the drug is still present in the tumor microenvironment. One
possible ”resistance mechanism” would thus be a slower proliferation rate.
Cancer cells that divide slower are less likely to attempt cell division while the
drug is present, and thus less likely to accumulate enough damage to trigger
apoptosis. When administration is stopped and the drug concentration goes
back down, surviving cells would then be able to repopulate the tumor. Using
constant drug exposure to generate resistant cells, as we did in the projects
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described in this thesis, the emerging resistance mechanisms may thus not
represent mechanisms that are commonly found in patient tumors. However,
the mechanisms observed offer important insights into the intracellular drug
metabolism and allow for studying how cancer cells adapt to drug treatment
and how it influences cell behavior.
Pancreatic cancer displays significant inherent resistance to chemotherapy,
often also in the absence of acquired resistance. In most cases even the initial
response to therapy is minimal. It is likely that other factors, such as penetration
and retention of small molecule drugs in pancreatic tumors play a dominant role
in determining the overall response to chemotherapy.
6.1.2 Relationship between cellular phenotype and chemoresistance
Previous research has suggested a strong correlation between cellular
EMT-status and resistance to gemcitabine. This correlation has been observed
in both directions, i.e. cells with acquired resistance to gemcitabine have
been observed to display EMT characteristics, and EMT has been indicated
to increase tumor resistance to therapy. It is possible that there is something
fundamental about a mesenchymal cellular state that is beneficial for cancer
cells in the context of drug resistance. Cancer cells in a mesenchymal state
not only proliferate slower, but also engage in fewer cell-cell interactions
and operate more independently from each other. It is possible that there
are disadvantages associated with being part of a tightly connected epithelial
colony when exposed to a cytotoxic drug. Some specialized cell-cell junctions
present in epithelial tissues, such as connexins/gap junctions, are able to traffic
small molecules directly between the cytoplasm of two adjacent cells and could
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thus potentially increase the penetration and distribution of a cytotoxic drug
into an epithelial-like cancer cell colony. Long-term exposure to the drug would
in this case select agains epithelial traits.
It also well established that epithelial tissues is some cases display
communal (non-autonomous) forms of cell death, where cell death-signaling
is propagated from cell to cell with in a population[153]. A mesenchymal state
could potentially protect against such signaling, but it is unclear how relevant
these types of cell death are in the context of cancer. One can also image a
protective effect of growing as a colony rather than as individual cells. Single
cells will be more exposed to the surrounding media containing the drug than
cells within an epithelial colony, which would result in a preference for an
epithelial phenotype.
When we set out to generate cell lines with acquired resistance to
gemcitabine we expected to find increased expression of EMT-makers and
increased EMT-like behavior across the board. However, although we observed
loss of epithelial characteristics in most of the cell lines generated, we did not
find EMT to be directly implicated in all cells. The EMT-program may be one
of many transcriptional programs that lead to similar effects in terms of loss of
epithelial phenotype and tissue organization. This may explain why we observe
loss of epithelial characteristics, but no clear EMT in the chemoresistant cells.
Formation of cohesive epithelial sheets also require coordination and correct
timing cell-cell of signaling and cell-cell junction formation. We observed
what appears to be dysregulation of cell-cell junctions in our resistant cells,
most likely resulting from genetic aberrations, such as passenger amplifications,
accumulated during the development of resistance. Dysregulation of cell-cell
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junctions may directly lead to the loss of epithelial characteristics, without
requiring the activation of an EMT program. This is emphasized by the fact
that we observe the same level of E-cadherin expression in gemcitabine resistant
BxPC-3 subclones as we do in sensitive cells, yet fewer cell-cell junctions, which
indicates dysregulation of cell-cell junctions rather than downregulation of
cell-cell junction components.
6.1.3 The effect of phenotypic heterogeneity on pancreatic
circulating tumor cell capture and tumor spheroids
It is well recognized that cancers display significant intra-tumor heterogeneity
and often consist of multiple coexisting subclones. There are many
processes that can potentially increase cellular heterogeneity of tumors.
The clonal development of cancer inherently leads to the development of
heterogeneous tumors[154]. In addition, cancer cells are exposed to many
types of growth-factor and cytokine-mediated signaling that may influence
cell phenotype. Growth-factor induced epithelial-to-mesenchymal transition
(EMT) is one example of signaling in the tumor microenvironment that has
the potential of increasing the heterogeneity of cancer cell populations. Cancer
cells receiving signaling from the microenvironment or from other cells will
thus display varying phenotype, despite constituting an isogenic population.
Furthermore, the signaling that takes place in the core of a tumor will differ
significantly from the signaling closer to the surface, at the intersection between
tumor and stroma, or in the vicinity of blood vessels. As a result the signaling
networks in a tumor can be assumes to complex, noisy, and unstable, leading to
significant cellular heterogeneity.
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In the projects described in this thesis, we found that EMT induction and
acquired resistance to gemcitabine significantly altered the phenotype and
behavior of pancreatic cancer cells. Within these in vitro models, we determined
the effect of EMT and chemoresistance on microfluidic CTC immunocapture. As
immunocapture relies on being able to distinguish cancer cells from blood cells
based on a difference in phenotype, processes that change the phenotype of the
target cells have serious implications for these isolation platforms. In particular,
we found that the loss in expression of the epithelial marker EpCAM resulted in
significant loss of capture performance, an observation that has implications for
the clinical implementation of positive-selection CTC technologies. In addition,
we identified EGFR capture as a potentially more robust capture modality, as
compared to EpCAM capture.
In a separate study, we observed striking effects of the acquisition of
chemoresistance on the tissue-level organizational characteristics of some
cancer cell populations. We found that acquired chemoresistance altered the
cell-sorting behavior of some cells and that chemoresistant cells preferentially
localize to the outside of tumor spheroids in some cases. The preferential
localization of resistant cells to the outside of spheroids, in combination with
the mechanism of drug resistance, results in chemoprotection of the cancer cell
population as a whole.
The protective effect of resistant cancer cells on non-resistant populations we
observe, suggests the possibility of cooperation between cancer cell populations
in tumors. In a different context, cooperation of antibiotic resistant and
non-resistant cell populations, resulting in mutually beneficial chemoprotection
has been observed in bacterial co-cultures[155]. It is thus not unreasonable
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to predict that this may also take place in some mammalian tumors. Indeed,
cooperation between cancer subpopulations has been suggested to occur also
human cancers and to potentially have clinical implications[154].
6.2 Future directions
6.2.1 Circulating epithelial cells as biomarkers for risk
stratification of patients with pancreatic cystic lesions
In this thesis we have shown feasibility of using captured circulating epithelial
cells (CECs) as biomarkers for risk-stratification of patients with precancerous
pancreatic cyst lesions. Immediate follow up studies to the work in this thesis
include, (1) comparing EpCAM, EGFR and MUC1 as targets for microfluidic
immunocapture of CTCs and CECs from patients samples, (2) a longitudinal
follow-up study of the patients screened in Chapter 2 to determine if CEC count
and phenotype correlates with evidence of carcinogenesis upon resection and
long-term survival, and (3) genetic analysis of captured CECs to determine
their connection to carcinogenesis. KRAS and GNAS mutations are indicated
in the progression of IPMNs to pancreatic cancer and could serve a appropriate
mutations to screen for in captured CEC[94].
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6.2.2 Cell-sorting in tumor spheroids
To understand the fundamental processes that control cell-sorting in tumor
spheroids further work is necessary. Our results thus far indicate that
cell-sorting is driven, in part, by dysregulation of cell-cell junctions and cell
junction-cytoskeleton interactions.
Phenotypic characterization of cells that sort in spheroid cultures point to a
potential role of Rho-familiy small GTPases. Specifically, RhoG may play a role
in the sorting behavior observed in Chapter 4. Following the same logic, the
potential role of STIM1 should be evaluated. siRNA-mediated knock-down of
RhoG and STIM1 may clarify their potential roles in cell-sorting. Alternatively,
RhoG or STIM1 could be knocked-in in naive cells. If possible, the transcriptome
of resistant and non-resistant BxPC-3 clones should be analyzed and compared
to rule out other potential mechanisms. It would also be interesting to see if
EMT-induction leads to cell-sorting in cancer cell populations, a question we
would be able to address directly using the models developed in Chapter 3 and
Chapter 4.
Works should also be undertaken to determine the generality of the
observation that chemoresistant cells preferentially localize to surface of
spheroids, as this may be of mechanistic and pathological significance. Other
cell culture systems, such as doxorubicin resistant MCF7 cultures should be
tested[156].
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